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Sous-titre de la thèse Rôle des CYP26s dans la métabolisation des medicaments 
Mots-clés CYP26A1, CYP26B1, CYP26C1, modélisation par homologie, 
acide rétinoïque, acide tazaroténique, adapalène, interactions 
protéine-ligand 
En l’absence de structures tridimensionnelles expérimentales des cytochromes P450 CYP26A1, 
CYP26B1 et CYP26C1, la caractérisation de leur substrats et ligands s’est basée sur l’analyse 
des modèles structuraux obtenus par modélisation par homologie avec la structure 
expérimentale du cytochrome P450 CYP120. La justesse des modèles a été validée par 
l’amarrage de l’acide rétinoïque all-trans dans des configurations compatibles avec les 
métabolites attendus. L’amarrage d’agonistes et d’antagonistes des récepteurs nucléaires 
RARs prédirent l’acide tazaroténique (TA) et l’adapalène comme des substrats potentiels. Les 
expériences in vitro confirmèrent la métabolisation de ces 2 médicaments par les CYP26s. 
L’analyse de la cinétique de sulfoxidation du TA par CYP26A1 and CYP26B1 a permis d’établir 
le TA comme la référence contrôle de l’activité de ces enzymes. Puis, la comparaison des 
modèles des CYP26s avec la structure cristalline de CYP2C8 a permis d’identifier des 
similarités structurales de leurs inhibiteurs. Une corrélation entre l’inhibition de CYP26A1 et de 
CYP2C8 par des inhibiteurs connus de CYP2C8 a été démontrée après détermination de leurs 
IC50 pour CYP26A1 et CYP26B1 en utilisant le TA comme substrat de référence. La mesure de 
l’inhibition in vitro fut ensuite utilisée pour évaluer la possibilité que les CYP26s soient 
impliquées dans des interactions médicamenteuses observées pour certaines molécules. Cette 
thèse caractérise et appuie le rôle encore mal connu des CYP26s dans la métabolisation in vivo 
de certains xénobiotiques ainsi que l’effet potentiel de leur inhibition qui favoriserait la survenue 
d'effets indésirables.  
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7. Chapter I: Introduction to Retinoic Acid Signaling and Cytochrome P450 26 
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7.1. Introduction. 
 Cytochrome P450 26A1 (CYP26A1), B1 (CYP26B1) and C1 (CYP26C1) are enzymes 
belonging to the cytochrome P450 superfamily of drug metabolizing enzymes that catalyze the 
metabolism of all-trans retinoic acid (at-RA) and related structural isomers.  Scientific interest in 
retinoic acid began to increase in the 1970s, while the study of the role of CYP26 in retinoic acid 
homeostasis began in the late 1990s (Figure 7-1).  As no crystal structures for any of the 
CYP26 isoforms have been solved to date, the majority of the structural characterization efforts 
for the enzyme subfamily have utilized a computational approach.  Further, while the catalysis of 
at-RA and related endogenous substrates has been the core of many robust scientific 
endeavors, the role of the enzymes in the metabolism of xenobiotic compounds and the 
inhibition of the enzymes by compounds other than retinoid-like molecules remains an area of 
considerable scientific focus.   
 The research presented in this thesis examined the metabolism and inhibition properties 
of CYP26 by xenobiotic compounds.  Homology models were designed for each isoform and 
initially validated using the known metabolic profile of at-RA.  Structural comparison of the active 
sites of the isoforms suggested similar hydrophobic binding regions proximal to the heme iron 
with differences in the amino acid residues distal to the heme and capable of stabilizing 
interactions with carboxylate moieties.  Active site volumes for CYP26A1, CYP26B1 and 
CYP26C1 were estimated at 918 Å3, 977 Å3 and 1090 Å3, respectively, suggesting the ability of 
each of the enzymes to accommodate the molecular volumes of typical xenobiotic ligands. As 
such, the models were utilized to assess the active site characteristics of each CYP26 isoform 
that are essential in describing their ligand binding abilities.  Based on homology model results, 
tazarotenic acid, adapalene and other retinoic acid receptor ligands were identified as metabolic 
substrates of CYP26.   
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Figure 7-1. Publications related to “Retinoic Acid” or “CYP26” sorted by year. 
 
 A comparison of the ligand binding characteristics of CYP26 and CYP2C8 pointed to a 
potential overlap between the inhibitory pharmacophores of the enzymes.  Indeed, when a set 
of known CYP2C8 inhibitors was screened for their ability to inhibit CYP26A1 or CYP26B1, a 
correlation was observed between the inhibitory potencies (IC50) for CYP2C8 and CYP26A1 (r2 
= 0.849), with clotrimazole being identified as a very potent inhibitor of both CYP26A1 and 
CYP26B1.  In the process, the use of tazarotenic acid sulfoxidation as a probe reaction for 
CYP26 activity in recombinantly expressed single enzyme systems was verified.  A cursory 
evaluation of the unbound Cmax concentrations and the IC50 values of the inhibitors in the 
screening set suggested the possibility for compounds such as clotrimazole or fluconazole to be 
involved in clinically-relevant drug interactions that involve CYP26.   
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 Collectively, the data presented in this thesis supports a significant role for CYP26 in 
both the metabolism of xenobiotics as well as xenobiotic drug interactions.  To date, one 
manuscript is in press and has been highlighted on the cover of the Journal of Pharmacology 
and Experimental Therapeutics (see Chapter II) and a second manuscript is currently under 
peer review (see Chapter III).  Future evaluations of the active site characteristics of CYP26A1, 
CYP26B1 and CYP26C1 that are integral to defining their substrate binding characteristics will 
increase the potential of identifying CYP26-selective inhibitors and may ultimately prove useful 
for the treatment of various disease states while increasing patient safety in regard to 
modulation of CYP26 activity in vivo. 
 
7.2. Retinoic Acid Signaling. 
The homeostatic control of endogenous retinoic acid concentrations is a highly conserved 
process because of its global role in the cellular lifecycle (Lotan, 1980; Sporn and Roberts, 
1984; McCaffery and Drager, 2000; Ross et al., 2000; Clagett-Dame and DeLuca, 2002; Maden, 
2002).  In humans, retinoic acid exerts its mechanism of action by binding to the retinoic acid 
and retinoid X receptors, regulating the expression of genes that are directly involved in cellular 
proliferation, differentiation and apoptotic processes (Figure 7-2) (Levin et al., 1992; 
Mangelsdorf et al., 1992; Mark et al., 2006; Altucci et al., 2007; di Masi et al., 2015).   Ligand-
bound retinoic acid and retinoid X receptors form a heterodimeric protein complex which 
subsequently binds to retinoic acid response element to elicit a physiological response (Giguere 
et al., 1987; Petkovich et al., 1987; Brand et al., 1988; Duester, 2008; Niederreither and Dolle, 
2008).  Endogenous ligands for the retinoic acid receptors include all trans-retinoic acid (at-RA), 
9-cis-RA and 13-cis-RA.  Additional evidence suggests that cellular retinoic acid binding 
proteins (CRABP-I and CRABP-II) are responsible for the facilitation and transport of retinoic 
acid with its cellular receptors (Fiorella and Napoli, 1991; Giguere, 1994; Noy, 2000). 
17 
 
Physiologically, retinoic acid signaling plays a key role in immune function, brain activity, 
spermatogenesis, dermatological regulation and organ development (Ransom et al., 2014; 
Cunningham and Duester, 2015).  Significant changes to circulating concentrations of retinoic 
acid are also known to factor into the onset or alleviation of various disease states (Miller, 1998; 
Kuenzli and Saurat, 2001; Njar, 2002; Ahmad and Mukhtar, 2004; Njar et al., 2006; Verfaille et 
al., 2008).    
 
 
Figure 7-2.  Retinoic acid signaling pathway. 
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7.3. Cytochrome P450. 
 The cytochrome P450s are a superfamily of heme-containing enzymes that are 
responsible for the oxidation or reduction of the majority of drugs currently in use (Ortiz de 
Montellano and De Voss, 2002).  The superfamily is comprised of over 57 individual enzymes in 
humans, though the major isoforms believed to be involved in drug metabolism are generally 
limited to CYP1A1, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, 
CYP3A4 and CYP3A5 (Guengerich, 2005).  Cytochrome P450s are predominantly localized to 
the endoplasmic reticulum of liver, intestinal, lung, kidney, brain and nasal mucosa cells (Ding 
and Kaminsky, 2003).  Cytochrome P450 isoforms involved in homeostatic processes include 
CYP4B1, CYP4F2, CYP4F12, CYP17A1, CYP19A1, CYP26 (A1, B1 and C1) and CYP46A1, in 
addition to many others.  They require the transfer of electrons from NADPH for catalytic 
activity, a process which occurs through interactions with multiple redox partners such as 
cytochrome P450 reductase and cytochrome b5 (Iyanagi and Mason, 1973; Vermilion and 
Coon, 1978; Vermilion et al., 1981; Schenkman and Jansson, 1999).  An abbreviated reaction 
cycle is shown in Figure 7-3. 
 From a protein conformation standpoint, the overall structure of cytochrome P450 
isoforms is relatively conserved across the family and appears designed specifically for 
catalyzing heme-thiolate reactions, interactions with cytochrome P450 reductase and 
cytochrome b5 and binding of endogenous and exogenous ligands (Poulous and Johnson, 
2005).  In general, structural conservation across family members increases as one is closer to 
the heme, and the I-helix of the different P450s is often used as a point of orientation in P450 
modeling and crystal structures.  Eukaryotic P450s are primarily membrane bound and located 
in the endoplasmic reticulum, with an N-terminal polypeptide chain responsible for anchoring the 
protein in the membrane (von Wachenfeldt et al., 1997; Cosme and Johnson, 2000; McDougle 
et al., 2013). 
 In addition to being involved in the metabolism of many endogenous and exogenous 
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ligands, the inhibition of cytochrome P450 isoforms plays an important role in both the 
regulation of homeostatic functions as well as in clinical drug interactions.  Inhibition of 
cytochrome P450 can be reversible (competitive, noncompetitive or mixed inhibition) or 
irreversible (mechanism-based inhibition) (Blobaum, 2006; Foti et al., 2010).  The mechanism of 
inhibition can also be characterized by the interactions between the ligand and the heme iron.  
Of particular note is the type II interaction that is often observed for compounds such as anti-
fungal compounds and select retinoids or retinoic acid metabolizing blocking agents, many of 
which contain an sp2 hybridized nitrogen capable of coordinating the heme iron.  Owing to the 
tendency of the heme-thiolate bond to stretch depending on the type of ligand interaction and 
the resulting change in the spin state of the heme iron, such interactions can be characterized 
through the use of various spectroscopic techniques (Schenkman and Jansson, 2006). 
 
Figure 7-3.  Cytochrome P450 reaction cycle. 
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7.4. Role of CYP26. 
 Endogenous control of retinoic acid occurs through increasing or decreasing its rate of  
synthesis, which can take place through the modulation of a number of catalytic processes 
through which retinol is converted to all-trans-retinoic acid (at-RA) or through altering the 
elimination or metabolism of retinoic acid, which occurs through oxidative metabolism catalyzed 
by cytochrome P450 enzymes, which are responsible for the oxidative metabolism of both drugs 
and endogenous substances (Figure 7-4) (Nelson, 2006; Duester, 2008; Niederreither and 
Dolle, 2008; Zanger and Schwab, 2013).  A subfamily within the cytochrome P450s, CYP26 
(CYP26A1, CYP26B1 and CYP26C1) is primarily responsible for the oxidative metabolism of 
retinoic acid (Ray et al., 1997; Lutz et al., 2009; Thatcher and Isoherranen, 2009; Thatcher et 
al., 2010; Ross and Zolfaghari, 2011).  CYP26A1 and CYP26B1 are the two most widely studied 
isozymes within the CYP26 family, with less known about the homeostatic and pharmacological 
significance of CYP26C1.  Similar to the channeling pathways reported for the retinoic acid and 
retinoid X receptors, CRABPs are also thought to be involved in the transport of retinoic acid to 
CYP26 to facilitate metabolism (Nelson et al., 2013b). The expression of both CYP26A1 and 
CYP26B1 have also been shown to be induced by retinoic acid, representing a major hurdle in 
the use of retinoic acid as a pharmacological intervention (Muindi et al., 1992; van der Leede et 
al., 1997; Wang et al., 2002; Wang et al., 2009).   
Quantitatively, CYP26 expression in the liver is primarily comprised of CYP26A1, with 
minimal amounts of hepatic CYP26B1 being present (Xi and Yang, 2008; Thatcher and 
Isoherranen, 2009; Thatcher et al., 2010; Topletz et al., 2012).  The highest levels of CYP26B1 
mRNA expression have been identified in the adult brain (White et al., 2000; Thatcher and 
Isoherranen, 2009; Topletz et al., 2012).  Extra-hepatically, both isozymes are ubiquitously 
expressed, with corresponding mRNA having been identified in skin, kidney, testes and lung 
(CYP26A1) or skin, lung, testes, placenta, ovaries and intestine (Ray et al., 1997; White et al., 
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2000; Wang et al., 2002; Xi and Yang, 2008; Tay et al., 2010; Thatcher et al., 2010; Osanai and 
Lee, 2011; Topletz et al., 2012; Nelson et al., 2013a).   
 
 
Figure 7-4.  Metabolic scheme for the formation and elimination of at-RA. 
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The evolutionary importance of regulating endogenous retinoic acid concentrations is 
consistent with the functional overlap of CYP26A1 and CYP26B1, though interestingly the two 
isoforms share only a 42 – 44% sequence homology (Taimi et al., 2004; Topletz et al., 2012).  
Knowledge of the metabolic ligand profiles of each enzyme is relatively sparse, with in-depth 
characterizations limited to retinoic acid isomers and structurally-related metabolites (White et 
al., 1996; Sonneveld et al., 1998; White et al., 2000; Taimi et al., 2004; Thatcher et al., 2010; 
Ross and Zolfaghari, 2011; Topletz et al., 2012; Topletz et al., 2014).  Previous reports 
indicated that the greatest catalytic efficiency is observed when all trans-retinoic acid (at-RA) is 
bound in the active site, though additional evidence suggests that CYP26A1, CYP26B1 and 
CYP26C1 are also able to catalyze the oxidative metabolism of other retinoic acid 
stereoisomers and structurally similar conformers.  (White et al., 1996; White et al., 2000; Taimi 
et al., 2004; Ross and Zolfaghari, 2011).  CYP26A1 and CYP26B1 are capable of catalyzing 
multiple steps in the metabolic clearance of at-RA (Figure 7-4), with roles in the sequential 
metabolism of 4-hydroxy-at-RA, 4-oxo-at-RA and 18-hydroxy-at-RA (Lutz et al., 2009; 
Shimshoni et al., 2012; Topletz et al., 2012; Topletz et al., 2014).   
 
7.5. CYP26 Pharmacology. 
Given the role of CYP26A1 and CYP26B1 in the endogenous control of retinoic acid 
concentrations in vivo, the identification of selective chemical inhibitors of the enzymes has 
been evaluated as a potential therapeutic approach in both inflammatory and oncological-
related disease states (Miller, 1998; Kuenzli and Saurat, 2001; Njar, 2002; Ahmad and Mukhtar, 
2004; Njar et al., 2006; Verfaille et al., 2008).  Initial attempts to identify inhibitors of CYP26A1 
or CYP26B1 resulted in the synthesis and characterization of retinoic acid metabolism blocking 
agents (RAMBAs).  The majority of known RAMBAs share a conserved pharmacophore, with a 
bridging hydrophobic tether that couples a hydrophobic or aromatic functional group to a 
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hydrogen bond acceptor, an observation which can be exploited to both characterize the active 
site binding characteristics of the enzymes as well as to design new inhibitors of the enzymes 
(Purushottamachar et al., 2012; Sun et al., 2015).  Often, the hydrophobic functional group is an 
azole-type moiety, integrated into the molecule to take advantage of a type II binding 
mechanism with the heme iron of CYP26A1 or CYP26B1, resulting in inhibition of the enzymes 
(Njar, 2002; Njar et al., 2006; Gomaa et al., 2008; Gomaa et al., 2011a; Thatcher et al., 2011; 
Nelson et al., 2013a).   
  Various structural analogs of retinoic acid, commonly referred to as retinoic acid 
receptor agonists or antagonists depending on their specific regulatory function, are also being 
pursued as therapeutic interventions across different therapeutic areas, including oncology, 
dermatology and regenerative medicine (Charpentier et al., 1995; Gudas and Wagner, 2011; di 
Masi et al., 2015).  Often, the understanding of the adsorption, distribution, metabolism and 
excretion characteristics of these compounds is limited.  However, the identification of these 
compounds has led to the evaluation of CYP26 as a potential drug target, as many of these 
compounds also have inhibitory activity against CYP26A1 or CYP26B1 (Thatcher et al., 2011).   
 
7.6. CYP26 Homology Modeling. 
 Characterization of the three-dimensional structure of a protein and, perhaps more 
importantly, its ligand binding regions can prove crucial to understanding the biological functions 
of a given drug target or metabolic enzyme.  Though a definitive assessment of a protein’s 
structure generally relies on experimentally-determined structural data, the prediction of the 
protein’s structure through homology modeling can also prove valuable in understanding the 
structural features which contribute to its ligand binding characteristics and biological 
mechanism of action (Hillisch et al., 2004; Cavasotto and Phatak, 2009).  A homology modeling 
approach aims to develop a computationally derived three-dimensional model for a protein with 
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an unknown structure based on its similarity to other proteins with experimentally determined 
structures (Lesk and Chothia, 1986; Murzin, 2001; John and Sali, 2003; Zhang, 2008).  The 
success of such an approach relies heavily on the degree of similarity between the two proteins 
as well as the generation of a correct sequence alignment between the two protein sequences 
(Khan et al., 2016).  The data generated through the use of a homology model can be used to 
identify endogenous substrates or rationally design new xenobiotic ligands for the protein of 
interest, whose observed binding properties in the active site of the protein can then be used to 
further refine the model (Hillisch et al., 2004).   
 The first step in developing a homology model is the selection of a template protein with 
a known three dimensional structure and high degree of sequence similarity to the target protein 
with unknown structure using either comparative sequence assessment, multiple sequence 
assessments such as hidden Markov models and intermediate sequence searches for 
secondary structure prediction and fold recognition or a threaded template matching approach 
(Berman et al., 2000; Westbrook et al., 2002; Saxena et al., 2013).  In general, a template 
structure with 30% or greater structural similarity to the target protein can provide the basis for a 
reliable homology model (Khan et al., 2016).  After identification of an appropriate template, the 
two protein sequences must be aligned in such a manner to provide the greatest degree of 
sequence alignment, using either dynamic programming algorithms designed to take a relatively 
insensitive approach to aligning two sequences or a more complex approach where the target 
sequence is aligned to the protein sequences of multiple related proteins or where position 
specific information is incorporated into the sequence alignment (Sanchez and Sali, 1997a; 
Sanchez and Sali, 1997b).  The latter approach becomes necessary for two proteins with less 
than optimal degrees of structural similarity (Xu et al., 1996; John and Sali, 2003). 
 Upon achievement of an acceptable degree of sequence alignment, a number of 
computational approaches are available with which to design and optimize the resulting 
homology model.  Perhaps the most widely used approach is model assembly using a subset of 
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rigid protein sequences that are derived from the overall target sequence (Browne et al., 1969; 
Blundell et al., 1987; Greer, 1990; Blundell et al., 2006).  A common approach to sub-dividing 
the protein sequence involves individually modeling the core backbone regions of the protein, 
followed by connecting variable loops and ultimately optimizing the individual amino acid side 
chains (Saxena et al., 2013).  Additional approaches include coordinate reconstruction, where 
the segmentation of the target protein into hexapeptide segments leads to the ultimate structural 
assignments, spatial restraint modelling, where geometrical deviations from the template 
structure using a set of pre-defined spatial restraints are minimized, or loop modeling, used to 
define flexible regions in a protein structure (generally less than eight amino acid residues) 
based on known libraries and conformational searching or energy-based approaches (Krieger et 
al., 2003; Saxena et al., 2013). 
Model optimization follows the initial model design.  Owing to the dynamic interplay 
between the predicted structure of the backbone core regions and the geometry of the individual 
side chains, an iterative approach is often utilized where the effects of energy minimization of 
the side chains on the backbone and vice-versa are taken into account over multiple cycles until 
the entire model eventually converges into a global energy minimum (Krieger et al., 2003).  In 
general, the energy minimization step is achieved by using either classical molecular dynamics 
or quantum force fields, which incorporate the positions of each atomic nucleus as well as the 
inherent charge distribution and treat the overall protein as a sum of the individual amino acids 
or a self-parameterizing force field, which build upon the aforementioned force fields by 
randomly changing a given parameter such as van der Waals radii and reminimizing the model 
to determine if an improvement in the model was obtained (Liu et al., 2001; Krieger et al., 2002). 
The final step in homology modeling is the validation of the model, which identifies errors 
inherent to all homology models.  As homology modeling is an inherently iterative process, 
errors in model design are easily propagated and can result in serious deficiencies in the final 
model design.  Commonly observed errors include sequence misalignments, incorrectly 
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assigned geographical sequences of the target protein, unacceptable side-chain conformations 
and abnormal bond lengths or angles (Morris et al., 1992; Czaplewski et al., 2000; Czaplewski 
et al., 2003; Krieger et al., 2003; Saxena et al., 2013).  Validation of the model can involve the 
entire model or distinct subdivided regions of the model, with each approach generating scoring 
functions that evaluate template alignment, protein stereochemistry and protein misfolding, in 
addition to a plentitude of other parameters (Sippl, 1995; Hooft et al., 1996; Marti-Renom et al., 
2000; Hillisch et al., 2004).  The scoring functions can generally be divided into either statistical-
based or physical-based energy functions (Sippl, 1995; Lazaridis and Karplus, 1999; Al-Lazikani 
et al., 2001; Xiang, 2006).  The former scoring functions incorporate the well-characterized 
properties of amino acids in a given structure while the latter is based on calculating the 
conformational free energy of the overall protein structure (Xiang, 2006).  
The homology models presented in this body of work were designed and validated using 
Prime (Schrodinger LLC, New York).  Within Prime, structural alignments are calculated using 
both the overall sequence of the target and template proteins as well as the secondary structure 
of each protein (Nayeem et al., 2006).  Contributions from protein structure, docked ligands, 
solvent and multiple force fields are combined to build the model using aligned atom positions.  
Nonaligned sequences between the target and template protein structures are calculated using 
solvation energies and ab initio approaches (Jacobson et al., 2004).  The simulations utilize the 
commonly used OPLS (Optimized Potential for Liquid Simulations) force field, developed by 
William Jorgensen (Jorgensen and Tirado-Rives, 1988).  The force field incorporates bonds and 
angles from known x-ray crystal structures, ab initio calculated dihedral angles, calculated 
partial charges from the equilibrated protein conformation and van der Waals parameters which 
account for solvent interactions (Weiner et al., 1984; Jorgensen and Tirado-Rives, 1988; 
Kaminski et al., 1994; Jorgensen et al., 1996; Mackerell, 2004; Jorgensen and Tirado-Rives, 
2005).  
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With respect to the structural characteristics of the cytochrome P450 family of drug 
metabolizing enzymes, their relatively flexible and lipophilic active sites can often pose a 
challenge in regard to accurately simulating the binding of a substrate within the active site and 
subsequently predicting the preferred site of metabolism (Williams et al., 2000; Lewis, 2002; 
Eksterowicz et al., 2014).  As no crystal structures currently exist, multiple CYP26A1 or 
CYP26B1 homology models are currently available, the majority of which have been used to 
characterize the ability of CYP26A1 to stereoselectively catalyze the formation of 4-(S)-OH-at-
RA or to investigate the ligand site interactions of azole-based inhibitors of CYP26A1 or 
CYP26B1 which are designed to coordinate to the heme iron and whose conformation in the 
active site can be confirmed through various spectral analyses (Gomaa et al., 2006; Gomaa et 
al., 2008; Karlsson et al., 2008; Ren et al., 2008; Gomaa et al., 2011a; Gomaa et al., 2011b; 
Shimshoni et al., 2012; Sun et al., 2015).   
8. Aims and Scope. 
The use of a homology model approach to identifying xenobiotic molecules which are 
capable of being metabolized by the CYP26 family of drug metabolizing enzymes is currently 
undefined and serves as the basis of the work presented in this thesis.  Homology models of 
CYP26A1, CYP26B1 and CYP26C1 were designed and utilized to compare the structural 
characteristics of each enzyme, especially in regard to active site architecture.  The models 
were validated through docking simulations with at-RA and subsequently utilized to identify and 
characterize tazarotenic acid as the first known xenobiotic substrate of CYP26.  Similar to 
earlier homology models, structural assessment of the models suggested active site similarities 
with CYP2C8, another cytochrome P450 isozyme capable of metabolizing at-RA (see Chapter 
II).  Tazarotenic acid was used as an in vitro probe of CYP26A1 or CYP26B1 activity to 
determine the inhibitory potency of set of known CYP2C8 inhibitors against CYP26 activity and 
the models applied to propose binding orientations for the most potent inhibitors (see Chapter 
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III).  Ultimately, in vitro inhibition properties were extrapolated to predicted in vivo outcomes in 
order to determine the ability of select CYP2C8 inhibitors to cause clinically meaningful drug 
interactions through inhibition of CYP26 activity.  Finally, the role of CYP26A1, CYP26B1 and 
CYP26C1 in the metabolism of additional retinoic acid agonists or antagonists was evaluated 
using in vitro experiments and computational modeling (see Chapter IV).  The metabolism of 
adapalene by CYP26 was evaluated and used to determine the ability of the CYP26 enzymes to 
alter the preferred sites of metabolism in response to sterically-hindering functional groups.  
Taken in their entirety, the results presented herein provide the basis for a significant role for the 
CYP26 family of drug metabolizing enzymes both in the metabolism of xenobiotic compounds 
as well as in the potential for clinical drug interactions through inhibition of CYP26-mediated 
catalytic pathways.   
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9.1. Introduction. 
 Cytochrome P450 26A1 and 26B1 are members of the cytochrome P450 superfamily of 
heme-containing enzymes that are responsible for the metabolism of retinoic acid (Ray et al., 
1997; Guengerich, 2006; Lutz et al., 2009; Thatcher and Isoherranen, 2009; Ross and 
Zolfaghari, 2011).  In addition to metabolizing retinoic acid, both CYP26A1 and CYP26B1 are 
induced by retinoic acid (Muindi et al., 1992; van der Leede et al., 1997; Wang et al., 2002; 
Wang et al., 2009).  The two enzymes are widely expressed throughout the adult human body, 
though CYP26A1 is the primary isoform expressed in the adult liver, with little to no hepatic 
expression of CYP26B1 observed (Xi and Yang, 2008; Thatcher and Isoherranen, 2009; 
Thatcher et al., 2010; Topletz et al., 2012).  CYP26B1 mRNA expression has been reported to 
be the highest in the adult brain (White et al., 2000; Thatcher and Isoherranen, 2009; Topletz et 
al., 2012).  Additional sites of expression for CYP26A1 mRNA include the skin, testes, kidney, 
and lung, while CYP26B1 mRNA has been identified in skin, lung, testes, placenta, ovaries and 
intestine (Xi and Yang, 2008; Osanai and Lee, 2011; Topletz et al., 2012).  While CYP26A1 and 
CYP26B1 share only a 42 – 44% sequence homology with each other, a significant amount of 
functional redundancy is observed between the two enzymes, indicating the importance of their 
role in the regulation of endogenous retinoic acid concentrations (Taimi et al., 2004; Topletz et 
al., 2012).  Reports on the catalytic activity of CYP26A1 and CYP26B1 are currently limited to 
various retinoic acid isomers and structurally-related metabolites (White et al., 1996; Sonneveld 
et al., 1998; White et al., 2000; Taimi et al., 2004; Thatcher et al., 2010; Ross and Zolfaghari, 
2011; Topletz et al., 2012; Topletz et al., 2014).  While the enzymes generally exhibit the 
highest degree of activity with all trans-retinoic acid (at-RA) as the substrate, they also 
metabolize other retinoic acid stereoisomers, albeit with much lower activities (White et al., 
1996; White et al., 2000; Taimi et al., 2004; Ross and Zolfaghari, 2011).  CYP26A1 and 
CYP26B1 also catalyze the in vitro clearance of the retinoic acid metabolites 4-hydroxy-at-RA, 
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4-oxo-at-RA and 18-hydroxy-at-RA (Lutz et al., 2009; Shimshoni et al., 2012; Topletz et al., 
2012; Topletz et al., 2014).   
Retinoic acid signaling and altered retinoic acid concentrations play a significant role in 
various disease states (Miller, 1998; Kuenzli and Saurat, 2001; Njar, 2002; Ahmad and Mukhtar, 
2004; Njar et al., 2006; Verfaille et al., 2008).  As a result of the contribution of CYP26A1 and 
CYP26B1 to retinoic acid metabolism, significant effort has gone into the design and synthesis 
of inhibitors of CYP26 activity, as increased retinoic acid concentrations have been considered 
beneficial in many instances.  Recent efforts to characterize CYP26 as a drug target have 
focused on structurally-related analogs of retinoids, retinoic acid metabolism blocking agents 
(RAMBAs) and retinoic acid receptor agonists, as a number of these compounds have been 
characterized as inhibitors of CYP26A1 activity in vitro (Thatcher et al., 2011).  While inhibitors 
of CYP26 have been identified, the role of these enzymes in the metabolism of xenobiotic 
compounds remains unclear.  Of special interest are the synthetic retinoic acid receptor 
agonists that are structurally similar to retinoic acid and have structural moieties which can 
undergo metabolism by cytochrome P450 enzymes.  One such retinoid is tazarotene, an 
acetylene-containing compound that is administered topically to stable plaque psoriasis or mild 
acne patients (Tang-Liu et al., 1999).  Tazarotene acts as a pro-drug in the skin with its activity 
being attributed to an active metabolite, tazarotenic acid, which binds with a high affinity to the 
retinoic acid receptors (Chandraratna, 1996).  The active metabolite shares key structural 
features with at-RA and has been reported to be metabolized by a number of drug metabolizing 
enzymes including CYP2C8, CYP3A4, FMO1 and FMO3 (Madhu et al., 1997; Tang-Liu et al., 
1999; Attar et al., 2003; Attar et al., 2005).  Whether tazarotenic acid is a substrate of CYP26A1 
and CYP26B1 is currently unknown.   
 In the absence of experimentally-determined structural data, homology modeling is a 
commonly applied computational technique used to predict protein structure and function 
(Hillisch et al., 2004; Cavasotto and Phatak, 2009).  The approach utilizes the known crystal 
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structure of a given protein to predict the three-dimensional properties of a second protein with a 
similar amino acid sequence but unknown structure (Lesk and Chothia, 1986; Murzin, 2001; 
Zhang, 2008).  The hypotheses generated by a homology model can be used to assess target 
druggability, to aid in the rational design of ligands for the given protein and to predict drug 
metabolism and toxicity, all of which can then be used to iteratively refine the model (Hillisch et 
al., 2004).  In regard to the cytochrome P450 family of drug metabolizing enzymes, the flexible 
and hydrophobic nature of their active sites often presents a challenge when attempting to use a 
homology model to accurately predict the site of metabolism for a given substrate (Williams et 
al., 2000; Lewis, 2002; Eksterowicz et al., 2014).  While it may be possible to correctly predict 
whether or not a ligand binds as an inhibitor of a cytochrome P450, correctly identifying the site 
of metabolism for a cytochrome P450 substrate may prove more challenging and can be 
indicative of the overall quality of the homology model (Arimoto, 2006; Yu et al., 2015).  Several 
homology models have been published for CYP26A1 and CYP26B1 and have been 
successfully used to rationalize the stereoselective product formation of 4-OH-at-RA by 
CYP26A1 or the binding of  triazole- or imidazole-containing inhibitors of CYP26A1 or CYP26B1 
within the active site of each enzyme (Gomaa et al., 2006; Gomaa et al., 2008; Karlsson et al., 
2008; Gomaa et al., 2011a; Gomaa et al., 2011b; Shimshoni et al., 2012; Sun et al., 2015).  
There are currently no homology models that compare the structure and function of CYP26A1 
and CYP26B1 based on the metabolism of a xenobiotic compound and attempts to crystallize 
either isoform have been largely unsuccessful. 
The aim of this work was to evaluate and characterize the active sites of CYP26A1 and 
CYP26B1 using homology modeling supported by at-RA and xenobiotic metabolism data.  
Homology models were constructed for each enzyme and compared for structural similarities 
and differences. at-RA and tazarotenic acid were docked into the active site of each enzyme 
and the predicted sites of metabolism evaluated.  Metabolite identification experiments in 
recombinantly expressed enzyme systems were used to confirm the hypotheses generated by 
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the homology models.  Finally, in vitro experiments were carried out to compare the metabolism 
of tazarotenic acid across a panel of drug metabolizing enzymes and to determine the kinetic 
parameters for the formation of metabolites from tazarotenic acid by CYP26A1 and CYP26B1.   
 
9.2. Materials and Methods. 
9.2.1. Materials. 
Tazarotenic acid and all metabolite standards were obtained from Tocris Chemicals (Bristol, 
United Kingdom).  CYP26A1 was expressed and characterized as previously described (Lutz et 
al., 2009).  All other reagents were obtained as noted below. Solvents were from Sigma-Aldrich 
(St. Louis, MO) and were of the highest grade available.   
 
9.2.2. Sequence Verification and Expression of CYP26B1.   
To express recombinant CYP26B1, the human CYP26B1 cDNA was obtained from OriGene 
Technologies (Rockville, MD) (catalog number TC120799). Upon sequencing of the obtained 
clone, two single nucleotide polymorphisms were discovered that differed from the sequence 
reported in NCBI (Q9NR63). The two SNPs were an A191G conversion resulting in an H>R 
amino acid change and a G788A conversion resulting in a G>S amino acid change 
(CYP26B1*1, Figure 9-1). To determine which of the possible SNPs would be reflective of the 
CYP26B1 sequence in the human population, genomic DNA was extracted from 12 human 
livers from the University of Washington human liver bank and the two sections of the CYP26B1 
gene were sequenced in all 12 donors.  In brief, genomic DNA (50 ng) was amplified by PCR 
using either forward (5’-TCTTTGAGGGCTTGGATCTG-3’) and reverse (5’-
GGCAGAGAGGGAAGG-3’) primers for the A191G SNP or forward (5’-
GACAAAGGGGAGAGGTGTCA-3’) and reverse (5’-GTAGAAATGGCTGGGCACAT-3’) primers 
for the G778A SNP at concentrations of 400 nM. The primers and template DNA together with a 
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Ready-to-Go bead (puReTaq Ready-to-Go PCR beads, Amersham Biosciences, Piscataway, 
NJ) were mixed in a final volume of 25 μL and PCR amplification was done as follows: after an 
initial denaturing step at 94°C for 4 min, amplification was performed for 32 cycles of 
denaturation (94°C for 30 s), annealing (55°C for 20 s), and extension (72°C for 30 s), followed 
by a final extension at 72°C for 30 s.  PCR products were analyzed by gel electrophoresis, spin 
column-purified to remove unincorporated nucleotides and primers using the QIAquick® PCR 
Purification Kit (Qiagen Inc., Hilden, Germany) and sequenced for the forward and reverse 
direction on an ABI Prism 377Xl DNA Sequencer (Applied Biosystems, Foster City, CA) with the 
ABI Prism® BigDyeTM Terminator Cycle Sequencing Ready Reaction Kit (PerkinElmer, Waltham, 
MA).  After the wild-type sequence was confirmed, the CYP26B1 coding sequence from the 
original clone was amplified while adding a 6xHis tag with a TEV cleavage site to maintain 
similarity with the commercially available clone as previously described (Topletz et al., 2012).  
CYP26B1 protein was expressed using the Bac-to-Bac baculovirus expression system (Life 
Technologies, Grand Island, NY) in Sf9 cells according to the manufacturer’s instructions as 
described previously (Topletz et al., 2012). Sf-900 II SFM liquid media (Life Technologies, 
Grand Island, NY) supplemented with 2.5% fetal bovine serum was used and during protein 
expression ferric citrate (0.2 mM) and δ-aminolevulinic acid (0.3 mM) were added to the media 
24 hours post-infection to facilitate heme synthesis. The cells were harvested 48 hours post 
infection, washed once in PBS with 1 mM PMSF, pelleted and stored at –80˚C.  Membrane 
fractions containing CYP26B1 were prepared by centrifugation as described previously (Topletz 
et al., 2012) and P450 content determined via CO-difference spectrum. 
9.2.3. IC50 Determination for Retinoic Acid Receptor Agonists.   
Six retinoic acid receptor agonists were assessed for in vitro inhibition of CYP26A1 and 
CYP26B1 catalyzed 9-cis-4-hydroxyretinoic acid formation.  Various concentrations of each 
inhibitor (0 – 100 µM) were incubated with 5 pmol CYP26A1 or CYP26B1, 10 pmol cytochrome 
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P450 reductase, and 100 nM 9-cis-retinoic acid in 100 mM potassium phosphate buffer (pH 
7.4).  Incubations were initiated by the addition of 1 mM NADPH (final concentration) and 
quenched after 2 minutes (CYP26A1) or 5 minutes (CYP26B1) with 5 volumes of ethyl acetate 
containing acitretin as an internal standard.  All samples were evaporated to dryness under a 
gentle stream of N2, reconstituted in methanol and assayed for 9-cis-4-hydroxyretinoic acid 
concentrations by HPLC-UV as previously described (Thatcher et al., 2011).  All IC50 
determinations were conducted in triplicate.  
9.2.4. Homology Modeling.   
Homology models of CYP26A1 and CYP26B1 were constructed using Prime (Schrodinger LLC, 
New York).  The amino acid sequence of human CYP26A1 was obtained from the NCBI protein 
server (GenBank ID: 2688846) and the CYP26B1 amino acid sequence was obtained as 
described above.  CYP120 (crystal structure, pdb 2VE3) was used as the template for both 
homology models.  Compared to CYP120, CYP26A1 had 33% sequence identity and 53% 
positive sequence coverage while CYP26B1 had 34% sequence identity and 54% positive 
sequence coverage.  The heme prosthetic group was added to each homology model and 
ligated to Cys442 (CYP26A1) or Cys441 (CYP26B1), followed by energy minimization prior to 
ligand docking using OPLS_2005 force field constraints as defined within the MacroModel 
algorithm (Schrodinger LLC, New York).  In order to flexibly dock at-RA, tazarotenic acid and 
tazarotenic acid sulfoxide, a ligand grid (12 x 12 x 12 Å) for which the center of mass of each 
ligand would be constrained to was defined and centered approximately 2 – 3 Å above the 
heme iron using Glide (Schrodinger LLC, New York).  Structural rationalization of each 
homology model was performed through the evaluation of Ramachandran plots and model 
assessment of odd bond lengths and angles (Figure 9-2).  Determination of model flexibility was 
assessed by comparison of helical versus loop motifs and by prediction of 2° structure 
characteristics using PSIPRED (University College London, UK) and SSPro (Schrodinger). 
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120         -------------------------------------MITSPTNLNSLPIPPGDFGLPWL 23 
26A1        -----MGLPALLA-SALCTFVLPLLLFLAAIKLWDLYCVSGRDRSCALPLPPGTMGFPFF 54 
26B1*1      MLFEGLDLVSALATLAACL-VSVTLLLAVSQQLWQLRWAATRDKSCKLPIPKGSMGFPLI 59 
26B1        MLFEGLDLVSALATLAACL-VSVTLLLAVSQQLWQLRWAATRDKSCKLPIPKGSMGFPLI 59 
                                                   :   .   **:* * :*:* : 
 
120         GETLNFLND-GDFGKKRQQQFGPIFKTRLFGKNVIFISGALANRFLFTKEQETFQATWPL 82 
26A1        GETLQMVLQRRKFLQMKRRKYGFIYKTHLFGRPTVRVMGADNVRRILLGDDRLVSVHWPA 114 
26B1*1      GETGRWLLQGSGFQSSRREKYGNVFKTHLLGRPLIRVTGAENVRKILMGEHHLVSTEWPR 119 
26B1        GETGHWLLQGSGFQSSRREKYGNVFKTHLLGRPLIRVTGAENVRKILMGEHHLVSTEWPR 119 
            *** . : :   * . ::.::* ::**:*:*:  : : **   * ::  :.. ... **  
 
120         STRILLGPNALATQMGEIHRSRRKILYQAFLPRTLDSYLPKMDGIVQGYLEQWGKAN--E 140 
26A1        SVRTILGSGCLSNLHDSSHKQRKKVIMRAFSREALECYVPVITEEVGSSLEQWLSCGERG 174 
26B1*1      STRMLLGPNTVSNSIGDIHRNKRKVFSKIFSHEALESYLPKIQLVIQDTLRAWSSHP-EA 178 
26B1        STRMLLGPNTVSNSIGDIHRNKRKVFSKIFSHEALESYLPKIQLVIQDTLRAWSSHP-EA 178 
            *.* :**   ::.   . *:.::*:: : *  .:*:.*:* :   :   *. * .      
 
120         VIWYPQLRRMTFDVAATLFMGEKVS------QNPQLFPWFETYIQGLFSLPIPLPNTLFG 194 
26A1        LLVYPEVKRLMFRIAMRILLGCEPQLAGDGDSEQQLVEAFEEMTRNLFSLPIDVPFSGLY 234 
26B1*1      INVYQEAQKLTFRMAIRVLLGFSIPEE----DLGHLFEVYQQFVDNVFSLPVDLPFSGYR 234 
26B1        INVYQEAQKLTFRMAIRVLLGFSIPEE----DLGHLFEVYQQFVDNVFSLPVDLPFSGYR 234 
            :  * : ::: * :*  :::* .        .  :*.  ::     :****: :* :    
 
120         KSQRARALLLAELEKIIKARQQQP------PSEEDALGILLAARDDNNQPLSLPELKDQI 248 
26A1        RGMKARNLIHARIEQNIRAKICGLRASEAGQGCKDALQLLIEHSWERGERLDMQALKQSS 294 
26B1*1      RGIQARQILQKGLEKAIREKLQCT----QSKDYLDALDLLIESSKEHGKEMTMQELKDGT 290 
26B1        RGIQARQILQKGLEKAIREKLQCT----QGKDYLDALDLLIESSKEHGKEMTMQELKDGT 290 
            :. :** ::   :*: *: :              *** :*:    :. : : :  **:   
 
120         LLLLFAGHETLTSALSSFCLLLGQHSDIRERVRQEQNKLQ--------LSQELTAETLKK 300 
26A1        TELLFGGHETTASAATSLITYLGLYPHVLQKVREELKSKGLLCKSN--QDNKLDMEILEQ 352 
26B1*1      LELIFAAYATTASASTSLIMQLLKHPTVLEKLRDELRAHGILHSGGCPCEGTLRLDTLSG 350 
26B1        LELIFAAYATTASASTSLIMQLLKHPTVLEKLRDELRAHGILHSGGCPCEGTLRLDTLSG 350 
              *:*..: * :** :*:   *  :  : :::*:* .            .  *  : *.  
 
120         MPYLDQVLQEVLRLIPPVGGGFRELIQDCQFQGFHFPKGWLVSYQISQTHADPDLYPDPE 360 
26A1        LKYIGCVIKETLRLNPPVPGGFRVALKTFELNGYQIPKGWNVIYSICDTHDVAEIFTNKE 412 
26B1*1      LRYLDCVIKEVMRLFTPISGGYRTVLQTFELDGFQIPKGWSVMYSIRDTHDTAPVFKDVN 410 
26B1        LRYLDCVIKEVMRLFTPISGGYRTVLQTFELDGFQIPKGWSVMYSIRDTHDTAPVFKDVN 410 
            : *:  *::*.:**  *: **:*  ::  :::*:::**** * *.* :**    :: : : 
 
120         KFDPERFTPDGSATHNPPFAHVPFGGGLRECLGKEFARLEMKLFATRLIQQFDWTLLPGQ 420 
26A1        EFNPDRFMLPHPED-ASRFSFIPFGGGLRSCVGKEFAKILLKIFTVELARHCDWQLLNG- 470 
26B1*1      VFDPDRFSQARSEDKDGRFHYLPFGGGVRTCLGKHLAKLFLKVLAVELASTSRFELATRT 470 
26B1        VFDPDRFSQARSEDKDGRFHYLPFGGGVRTCLGKHLAKLFLKVLAVELASTSRFELATRT 470 
             *:*:**           * .:*****:* *:**.:*:: :*:::..*     : *     
 
120         --------------------------------------------------- 420 
26A1        PPTMKTSPTVYPVDNLPARFTHFHGEINLELVVTPSPRPKDNLRVKLHSLM 521 
26B1*1      FPRITLVPVLHPVDGLSVKFFGLDSNQNEILPETEA-----MLSATV---- 512 
26B1        FPRITLVPVLHPVDGLSVKFFGLDSNQNEILPETEA-----MLSATV---- 512 
 
Figure 9-1.  Multiple sequence alignment of CYP120, CYP26A1, CYP26B1*1 and CYP26B1 
amino acid sequences. 
The sequence identity between CYP26A1 and CYP26B1, CYP26B1*1 and CYP120 was 44.47%, 44.26% and 33.26%, respectively.  
For CYP26B1*1, a 99.61% and 34.69% sequence identity was observed with CYP26B1 and CYP120, respectively.  Amino acids 
are represented in red (small/hydrophobic), blue (acidic), purple (basic) and green (hydroxyl/sulfhydryl/amine).  Sequence 
consensus is indicated by an asterisk (residue is fully conserved across all sequences), a colon (consensus group contains very 
similar properties) or a period (consensus group contains weakly similar properties).   
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Ligand structures were also minimized using the OPLS_2005 force field constraints within 
LigPrep (Schrodinger LLC, New York).  GlideScore and eModel scoring algorithms were used to 
assess the docking poses of the ligands within the active site of each enzyme (Friesner et al., 
2004; Friesner et al., 2006).  The use of the eModel scoring algorithm allowed for selection of 
the best docking pose based upon the GlideScore, grid score and ligand score of each docked 
ligand (Perola et al., 2004).  The hydrogen atoms nearest the heme iron for the at-RA and 
tazarotenic acid docking poses with the highest GlideScores and eModel scores were used as 
the predicted sites of oxidative metabolism for each compound.  The volume of the active site 
within each homology model was estimated using DoGSiteScorer (Volkamer et al., 2012). 
 
 
Figure 9-2.  CYP26A1 and CYP26B1 Ramachandran Plot. 
Analysis of the Phi-Psi angles in the CYP26A1 and CYP26B1 homology model demonstrated 
98.9% and 98.3%, respectively, were in the favorable or allowable regions. 
 
 
 
 
A B
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9.2.5. Metabolic Profiling.   
Due to its relative potency in the CYP26A1 and CYP26B1 inhibition assays, tazarotenic acid 
was selected for further evaluation.  In vitro experiments to elucidate the metabolic pathways of 
tazarotenic acid in CYP26A1 and CYP26B1 recombinant preparations were carried out using 
previously optimized conditions of 20 nM recombinant enzyme, 200 nM purified human 
reductase and tazarotenic acid (10 µM) in 100 mM potassium phosphate buffer (pH 7.4; final 
volume 100 µL).  Incubations were initiated with the addition of 1 mM NADPH (final 
concentration) and incubated at 37 ºC for 30 minutes.  Control incubations were performed in 
the absence of NADPH.  Subsequent incubations to confirm the sequential metabolism of 
tazarotenic acid by CYP26A1 and CYP26B1 utilized 10 µM tazarotenic acid sulfoxide (final 
concentration) as the substrate in the incubation.  Upon completion, in vitro incubations were 
extracted into 4 volumes of ethyl acetate, dried under a gentle stream of N2 at 40 ºC and 
reconstituted in 100 µL methanol prior to LC-MS/MS analysis and compared to synthetic 
standards of each metabolite, if available.  LC-MS/MS analysis was performed as described 
below.   
 
9.2.6. Enzyme Kinetics.   
In vitro enzyme kinetic parameters were determined for tazarotenic acid metabolite formation 
using 5 nM CYP26A1 or CYP26B1, 25 nM purified human reductase and 0 – 10 µM tazarotenic 
acid.  Incubations were carried out for 10 minutes at 37 ºC to ensure product linearity with 
regard to time and protein concentration.  Additional experiments to determine the kinetic 
parameters for the sequential metabolism of tazarotenic acid metabolite sulfoxide used 
substrate concentrations ranging from 0 – 50 µM.  Samples were prepared as described for in 
vitro metabolic profiling experiments. 
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9.2.7. Tazarotenic Acid Phenotyping.   
To assess the relative contribution of CYP26A1 and CYP26B1 to the in vitro oxidative 
metabolism of tazarotenic acid, metabolite formation was monitored across a panel of drug 
metabolizing enzymes.  Previously reported studies to characterize the enzymes responsible for 
the metabolism of tazarotenic acid were conducted at substrate concentrations of 1 – 200 µM 
(Attar et al., 2003).  As total circulating plasma concentrations of tazarotenic acid are 
approximately 1 – 280 nM following typical doses of tazarotene, current studies were conducted 
using clinically relevant substrate concentrations.  In vitro incubations consisted of 5 nM 
recombinant enzyme, 50 nM purified human reductase and 100 nM tazarotenic acid (final 
concentrations) in 100 mM potassium phosphate buffer (pH 7.4).  Following a three minute pre-
incubation at 37 ºC, reactions were initiated with the addition of 1 mM NADPH (final 
concentration).  For incubations utilizing flavin-containing monooxygenase enzymes, the pre-
incubation step consisted of enzyme and NAPDH followed by initiation with substrate due to the 
known instability of FMOs at 37 ºC in the absence of cofactor (Foti and Fisher, 2004).  
Incubations (50 µL, final volume) were carried out for 30 minutes at 37 ºC before being 
quenched with 3 volumes (v/v) of ice-cold acetonitrile containing tolbutamide as an internal 
standard.  Samples were vortexed and centrifuged at 1240 x g for ten minutes before being 
transferred for LC-MS/MS analysis.  Data was expressed as the percent of total metabolite 
formed across the panel of enzymes for each individual metabolite. 
 
9.2.8. LC-MS/MS Analysis.   
Analysis of tazarotenic acid and its metabolites was conducted using LC-MS/MS.  The analytical 
platform was comprised of an Applied Biosystems API4000 fitted with an electrospray ionization 
source (Applied Biosystems, Foster City, CA).  Liquid chromatography and sample introduction 
was achieved using two LC-20AD binary pumps with an in-line DGU-20A5 solvent degasser 
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(Shimadzu, Columbia, MD) and a LEAP CTC HTS PAL autosampler (CTC Analytics, Carrboro, 
NC).  An injection volume of 10 μL was used for all analyses.  For enzyme kinetic experiments, 
chromatographic separation was achieved using 0.1% formic acid (v/v) in water (mobile phase 
A) and 0.1% formic acid in methanol:acetonitrile (1:1; mobile phase B) on a Synergi 2.5 µm 
Hydro RP 100 Å (50 x 2.0 mm) column (Phenomenex, Torrance, CA).  Gradient conditions 
consisted of 2.5% B (0 – 0.4 minutes), 2.5% B – 95% B (from 0.4 – 1.4 minutes), 95% B (from 
1.4 – 2.5 minutes) and re-equilibration at 2.5% B for 0.5 minutes.  For metabolite identification 
experiments, the same mobile phase system was used with a Kinetex 2.6 µm C18 100 Å (100 x 
2.1 mm) column (Phenomenex, Torrance, CA).  A gradient of 2.5% B (0 – 3 minutes), 2.5% B – 
95% B (from 3 – 14 minutes), 95% B (from 14 – 17 minutes) followed by re-equilibration at 2.5% 
B for 3 minutes was used to achieve chromatographic separation of all analytes.  Initial 
metabolite identification experiments used full scan analysis from 100 – 800 amu followed by 
analysis of the corresponding product ion spectra for each observed analyte.  Subsequent LC-
MS/MS analyses utilized multiple reaction monitoring (MRM) for each analyte.  MRM transitions 
(positive ionization mode) were as follows: tazarotenic acid (m/z 324.2 / 294.3), tazarotenic acid 
sulfoxide and hydroxytazarotenic acid (m/z 340.3 / 280.3), tazarotenic acid sulfone (m/z 356.3 / 
276.3) and the internal standard tolbutamide (m/z 271.2 / 91.1).  Generic parameters applied to 
all MS analyses included the curtain gas (12 arbitrary units), CAD gas (medium), ion spray 
voltage (5000 V), source temperature (500 °C) and ion source gas 1 and gas 2 (30 arbitrary 
units, each). 
 
9.2.9. Data Analysis.   
Mass spectrometry data was evaluated using Analyst (version 1.5; Applied Biosystems, Foster 
City, CA).  Analyte concentrations were determined by comparing peak areas in unknown 
samples to those obtained from standard curves with analytical standards (dynamic range: 1 – 
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2000 nM; weighting: 1/x).  Parameter fitting for IC50 and enzyme kinetic data was performed 
using Graphpad Prism as described below (version 6.03; Graphpad Software Inc., San Diego, 
CA).    
IC50 values for retinoic acid receptor agonists in the 9-cis-4-hydroxyretinoic acid assay 
were determined by nonlinear regression using Equation 1.  In the following equation, 
100%*(Vi/V) represents the percent activity remaining for a given inhibitor concentration, [I], 
(Vi/V)max*100% is the maximum observed activity with no inhibitor present, and (Vi/V)min is the 
remaining enzyme activity at infinitely high concentrations of inhibitor.   
Equation 1  
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Enzyme kinetic parameters (Km and Vmax) were estimated through nonlinear regression 
analysis using the Michaelis-Menten model as shown in Equation 2.  In the equation below, Km 
denotes half the substrate concentration ([S]) at maximal reaction velocity (Vmax).   
 
Equation 2  
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9.3. Results. 
9.3.1. Homology Modeling.   
Characterization of CYP26B1 from a commercially available clone (OriGene, Rockville, MD) and 
set of 12 human livers identified two amino acids which differed from the currently accepted 
amino acid sequence of the enzyme (Figure 9-1).  The two sequencing differences were an 
A191G substitution resulting in an H64R amino acid change and a G778A substitution resulting 
in a G260S amino acid change.  All 12 human donors sequenced had a CYP26B1 sequence 
identical to the clone obtained from OriGene and did not have the two sequencing differences 
observed in the previously reported clone of CYP26B1 (UniProtKB Q9NR63). Therefore the 
sequence with arginine at position 64 and serine in residue 260 was accepted as the wild type 
sequence of CYP26B1 (CYP26B1*1). The sequence of CYP26B1*1 is shown in Figure 9-1 and 
was used to build the subsequent CYP26B1 homology model.  In order to assess the active 
sites of CYP26A1 and CYP26B1, homology models of each enzyme were constructed using the 
crystal structure of CYP120 (pdb 2VE3), which showed the highest degree of sequence 
similarity with CYP26A1 or CYP26B1 in a BLAST search.  Sequence analysis indicated 
CYP26A1 had a sequence identity of 44.47% with CYP26B1 (Q9NR63), 44.26% with 
CYP26B1*1 and 33.26% with CYP120 (2VE3).  CYP26B1*1 had a 99.61% sequence identity 
with CYP26B1 (Q9NR63) and a 34.69% sequence identity with CYP120.  Superimposition of 
the CYP26A1 or CYP26B1 homology models with the template structure (CYP120) resulted in 
RMSD values of 1.038 and 1.168, respectively.  Superimposition of the CYP26A1 and 
CYP26B1 homology models with each other resulted in a RMSD value of 1.651.  Similarities in 
hydrophobic binding residues were observed for CYP26A1 and CYP26B1, with W112, Phe222 
and Phe299 occupying analogous positions in the CYP26A1 active site as W117, Phe222 and 
Phe295 in the CYP26B1 active site (Figure 9-3).  A greater divergence was observed for those  
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Table 9-1.  Estimated parameters for CYP26A1 and CYP26B1 homology models. 
Parameter CYP26A1 Model CYP26B1 Model 
Template CYP120 (pdb 2VE3) CYP120 (pdb 2VE3) 
Template Sequence Identity 33% 34% 
Template Positive Sequence Coverage 53% 54% 
BLAST Query Coverage 89% 89% 
BLAST E-Value 2e-82 6e-91 
RMSD vs Template 1.038 1.168 
Favorable Bond Angles 86.2% 95.0% 
Allowable and Favorable Bond Angles 98.9% 98.3% 
I-Helix Residues M287 – L318 M283 – A304 
Active Site Volume 918.01 Å3 976.86 Å3 
at-RA Docking Score (4-(S)-OH) -9.552 -4.999 
at-RA Distance from Heme (4-(S)-OH) 3.85 Å 2.99 Å 
at-RA Docking Score (4-(R)-OH) N/A -4.128 
at-RA Distance from Heme (4-(R)-OH) N/A 4.06 Å 
at-RA Docking Score (16-OH) -9.552 -4.488 
at-RA Distance from Heme (16-OH) 3.49 Å 2.77 Å 
at-RA Docking Score (18-OH) -9.552 -4.435 
at-RA Distance from Heme (18-OH) 5.10 Å 3.10 Å 
Tazarotenic Acid Docking Score -11.016 -9.172 
Tazarotenic Acid Distance from Heme 4.21 Å (to sulfur) 4.11 Å (to sulfur) 
Tazarotenic Acid Sulfoxide Docking Score -11.912 -9.843 
Tazarotenic Acid Sulfoxide Distance from 
Heme 
4.38 (to sulfur) 3.58 Å (to sulfur) 
 
 
amino acid residues potentially capable of stabilizing the carboxylate moiety of at-RA in the 
active site of CYP26A1 (Arg64, Arg86 and Arg90) and CYP26B1 (W65, Arg76, Tyr372 and 
Arg373).  Parameters detailing the structural evaluation of the template and the model are 
shown in Table 9-1 with the corresponding Ramachandran plots shown in Supplemental Figure 
9-2.  The active site volumes of CYP26A1 and CYP26B1 were estimated to be 918 Å3 and 977 
Å3, respectively.   
To further assess the validity of the homology models, at-RA was docked into the active 
site of the CYP26A1 and CYP26B1 homology models.  In both models, the β-ionone ring of at-
RA was oriented towards the heme iron, with the models confirming that the hydrogen atoms at  
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Figure 9-3. Structural alignment of CYP26A1 (orange) and CYP26B1 (cyan) homology 
models. 
Sequence alignment of the two homology models indicated a structural identity of 44.26% and 
an RMSD value of 1.651.  Structural similarity was observed for the portion of the active site of 
each enzyme that may contribute to hydrophobic binding interactions with a given ligand 
(Trp112, Phe222 and Phe299 for CYP26A1; Trp117, Phe222 and Phe295 for CYP26B1).  The 
active site volumes of CYP26A1 and CYP26B1 were estimated to be 918 Å3 and 977 Å3, 
respectively.   
 
the 4-, 16- or 18-position of the β-ionone ring of at-RA were positioned toward the heme iron.  
Similar to previously published homology model results, a single docking orientation of at-RA in 
the active site of CYP26A1 was able to account for oxidation at the 4-, 16- and 18- positions 
(Shimshoni et al., 2012).  Further, only the hydrogen atom which when abstracted would lead to 
formation of the 4-(S)-hydroxyretinoic acid metabolite was directed toward the heme iron at a 
distance of 3.85 Å, with the hydrogen atoms at the 16- and 18- positions approximately 3.49 Å 
and 5.10 Å away from the heme iron, respectively (Figure 9-4A and Figure 9-5).  In this 
F295
F222
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orientation, the corresponding hydrogen to form 4-(R)-hydroxyretinoic acid was directed away 
from the heme iron in a metabolically unfavorable position at a distance of 5.59 Å.  The 
CYP26A1 homology model was unable to resolve an orientation of at-RA in the active site 
conducive with abstraction of the hydrogen in the 4-(R)-position.  Conversely, docking 
orientations where either hydrogen atom on the carbon atom at the 4-position of the β-ionone 
ring was oriented toward the heme iron were identified using the CYP26B1 homology model 
(Figure 9-4B), suggesting that formation of 4-hydroxyretinoic acid by CYP26B1 would not be 
stereoselective.  For formation of 4-(R)-hydroxyretinoic acid (Figures 9-4B (orange structure) 
and Figure 9-5), the hydrogen atom was located approximately 4.06 Å from the heme iron.  
When docked in such a way that the resulting product would be 4-(S)-hydroxyretinoic acid 
(Figures 9-4B (cyan structure) and Figure 9-5), the hydrogen atom to be abstracted was 
positioned approximately 2.99 Å from the heme iron.    Docking of at-RA in the CYP26B1 
homology model such that 16-hydroxyretinoic acid (Figures 9-4C and Figure 9-5) or 18-
hydroxyretinoic acid (Figures 9-4D and Figure 9-5) would be the expected products positioned 
the sites of metabolism approximately 2.77 Å and 3.10 Å from the heme iron, respectively.  The 
CYP26B1 docking score for the at-RA orientation leading to formation of 4-(S)-hydroxyretinoic 
acid was slightly more favorable than that leading to formation of 4-(R)-hydroxyretinoic acid and 
was similar to the docking scores observed when the 16- or 18-position was oriented toward the 
heme iron (Table 9-1).  Arg90 (CYP26A1) and Ser369 or Arg373 (CYP26B1) were located 
within 3 Å of the carboxylic acid moiety of at-RA.  Amino acid residues depicted in Figure 9-4 
and Figure 9-5 are located within 3 Å of the docked at-RA ligand.   
In order to select a non-endogenous retinoid-like molecule to include in the homology 
model analysis, a panel of retinoic acid receptor agonists was screened for inhibitory potency 
against CYP26A1 and CYP26B1.  IC50 values ranged from 3.7 – 18 µM for CYP26A1 and from 
0.13 – 31 µM for CYP26B1 (Table 9-2).  Tazarotenic acid was the second most potent inhibitor  
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Figure 9-4.  CYP26A1 (A) and CYP26B1 (B – D) homology models with at-RA docked in 
the active site. 
A single docking orientation of at-RA in the CYP26A1 homology model accounted for 4-, 16- 
and 18-hydroxylation of at-RA and suggested that abstraction of the hydrogen atom leading to 
formation of 4-(S)-hydroxy-at-RA was the preferred binding orientation for CYP26A1, supporting 
the reported stereoselective metabolism of at-RA by CYP26A1 (A).  Alternatively, docking of at-
RA in the active site of CYP26B1 suggested that orientation of either hydrogen atom at the pro-
chiral 4-position of the beta-ionone ring towards the heme iron was equally favorable, in 
agreement with the observed formation of both 4-(R)-hydroxy- (orange structure) and 4-(S)-
hydroxy-at-RA (cyan structure) by CYP26B1 (B).  The CYP26B1 model was also capable of 
docking at-RA such that the 16-hydroxy- or 18-hydroxyretinoic acid metabolites would be the 
predicted metabolite products (C and D).  
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Figure 9-5.  Ligand interaction diagram for at-RA docked in the active site of CYP26A1 
and CYP26B1. 
Analysis of the active site ligand interactions for at-RA docked in the active site of CYP26A1 (A) 
and CYP26B1 (4-(R)-OH, B; 4-(S)-OH, C; 16-OH, D; 18-OH,  E) shows the hydrophobic 
(green), hydrophilic (blue), electrostatic (red/purple) and metal (pink) interactions located within 
3.0 Å of at-RA.  Hydrogen bonding interactions are depicted by dashed lines.   
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from the panel against CYP26A1, the most potent inhibitor against CYP26B1 and the only 
inhibitor to exhibit low to sub-micromolar inhibition potency in both assays.  As such, it was 
selected for further evaluation in the CYP26A1 and CYP26B1 homology models.   
 
   
Table 9-2.  CYP26A1 and CYP26B1 IC50 values for retinoic acid receptor agonists and 
their derivatives (95% confidence interval is shown in parentheses). 
 
RAR Agonist CYP26A1 IC50 (µM) CYP26B1 IC50 (µM) 
AM80 
12 
(8.1 – 18) 
6.6 
(2.3 – 19) 
AM580 
5.6 
(3.0 – 10) 
2.2 
(1.4 – 3.2) 
BMS753 
18 
(4.4 – 76) 
28 
(21 – 37) 
BMS961 
14 
(9.6 – 20) 
31 
(15 – 63) 
Tazarotenic Acid 
6.1 
(3.2 – 12) 
0.13 
(0.09 – 0.19) 
TTNPB 
3.7 
(1.4 – 9.8) 
3.4 
(2.2 – 5.2) 
 
 
 
A single binding orientation was observed for tazarotenic acid in the CYP26A1 homology 
model with the heme iron located approximately 4.21 Å from the sulfur atom of the 
benzothiopyranyl ring and 5.15 Å from the adjacent aromatic hydrogen (Figure 9-6A).  Key 
amino acids involved in ligand binding with CYP26A1 included Met60, Arg90, Trp112, Leu120, 
Phe222, Phe299, Thr304, Val370, Pro371, Gly372, Thr476, Pro478, and Thr479 (Figure 9-7).  A 
hydrogen bonding interaction was predicted between the carboxylic acid moiety of tazarotenic 
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acid and Arg90.  The observed docking pose would predict either sulfoxidation or hydroxylation 
to occur on the benzothiopyranyl ring of tazarotenic acid.  Similar active site interactions were 
predicted when tazarotenic acid sulfoxide was docked in the active site of CYP26A1, with the 
sulfur atom and adjacent aromatic hydrogen atom 4.38 Å and 3.16 Å away from the heme iron, 
respectively (Figure 9-6B).  Hydrogen bonding was predicted to occur between the carboxylate 
group of tazarotenic acid sulfoxide and Arg90 and between the pyridinyl nitrogen and Gly372 
(Figure 9-7).  Docking of tazarotenic acid in the active site of CYP26B1 resulted in a pose 
similar to that identified for 16-hydroxylation of at-RA, with hydrogen bonding interactions 
between the substrate and Arg373 and Ile396 stabilizing the carboxylic acid moiety of 
tazarotenic acid.  In this orientation, the sulfur and adjacent aromatic hydrogen atom were 
located approximately 4.11 Å and 4.07 Å from the heme iron, respectively (Figures 9-6C and 
Figure 9-7).  Tazarotenic acid sulfoxide bound in a similar manner in the active site of CYP6B1, 
with the sulfur and adjacent aromatic hydrogen atom located approximately 3.58 Å and 3.53 Å 
from the heme iron (Figure 9-6D).   Hydrogen bonds were predicted between the carboxylate of 
tazarotenic acid sulfoxide and Arg373 and Ile396, as well as between the pyridinyl nitrogen of 
tazarotenic acid sulfoxide and Asp398 (Figure 9-7).  Similar to the docking poses obtained with 
CYP26A1, results from the CYP26B1 homology model would predict metabolism to occur on 
the benzothiopyranyl moiety of tazarotenic acid or tazarotenic acid sulfoxide, with the sulfur 
atom generally in closest proximity to the heme iron.   
 
9.3.2. Metabolic Profile.   
The oxidative metabolites of tazarotenic acid whose formation are catalyzed by CYP26A1 and 
CYP26B1 were characterized using recombinant enzymes.  Metabolism of tazarotenic acid by 
CYP26A1 and CYP26B1 resulted in the formation of tazarotenic acid sulfoxide, tazarotenic acid 
sulfone and a hydroxylated metabolite of tazarotenic acid (Figure 9-8).  Comparison of the 
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electrospray ionization fragmentation patterns of the tazarotenic acid and tazarotenic acid 
sulfoxide synthetic standards with the hydroxylated metabolite of tazarotenic acid suggested 
that the location of the hydroxyl moiety was an aromatic hydroxylation on the benzothiopyranyl 
ring system (Figures 9-9 and 9-10).  Formation of all tazarotenic acid metabolites was NADPH 
dependent.  In order to assess the sequential metabolism of tazarotenic acid by CYP26A1 and 
CYP26B1, incubations were conducted using tazarotenic acid sulfoxide as the starting material.  
Both CYP26A1 and CYP26B1 catalyzed the metabolism of tazarotenic acid sulfoxide to 
tazarotenic acid sulfone (Figure 9-8).  A proposed metabolic scheme is shown in Figure 9-11.   
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Figure 9-6.  CYP26A1 and CYP26B1 homology models with tazarotenic acid docked in the 
active site. 
Docking of tazarotenic acid in the active sites of CYP26A1 (A) and CYP26B1 (C) suggested 
metabolism at or near the sulfur atom of the benzothiopyranyl ring system was the preferred site 
of metabolism.  Similar binding orientations were observed for tazarotenic acid sulfoxide in the 
active sites of CYP26A1 (B) or CYP26B1 (D). 
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Figure 9-7.  Ligand interaction diagram for tazarotenic acid or tazarotenic acid sulfoxide 
docked in the active site of CYP26A1 and CYP26B1. 
Analysis of the active site ligand interactions for tazarotenic acid docked in the active site of 
CYP26A1 (A) and CYP26B1 (C) shows the hydrophobic (green), hydrophilic (blue), electrostatic 
(red/purple) and metal (pink) interactions located within 3.0 Å of tazarotenic acid.  Ligand 
interactions for tazarotenic acid sulfoxide in the active site of CYP26A1 (B) and CYP26B1 (D) 
are also shown.  Hydrogen bonding is depicted by dashed or solid lines.    
 
9.3.3. In Vitro Enzyme Kinetics.   
The enzyme kinetic parameters describing the formation of tazarotenic acid sulfoxide and 
hydroxytazarotenic acid were determined for CYP26A1 and CYP26B1.  Enzyme kinetic 
parameters were determined using Michaelis-Menten kinetics and are reported in Table 9-3 and 
shown in Figure 9-12.  In general, incubations with CYP26B1 resulted in slightly higher Km and 
kcat values as compared to incubations conducted with CYP26A1.  Intrinsic clearance values 
(calculated as Vmax / Km) were slightly higher for CYP26A1 as compared to CYP26B1 owing 
A B
C D
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primarily to the difference in Km values between the two enzymes.  Both enzymes appeared to 
favor formation of the hydroxylated metabolite of tazarotenic acid.  Formation of tazarotenic acid 
sulfone from tazarotenic acid sulfoxide was linear through a substrate concentration of 50 µM 
and as such no kinetic parameters were determined for this metabolic pathway.   
 
Figure 9-8.  Extracted ion chromatograms for the metabolic profile of tazarotenic acid (A) 
and tazarotenic acid sulfoxide (B) by CYP26A1 and CYP26B1. 
Data sets are offset for clarity and control traces represent incubations conducted in the 
absence of NADPH.   
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Figure 9-9.  MRM spectra for tazarotenic acid and metabolites. 
MS-MS Spectrum For Tazarotenic Acid (m/z 324.2), Tazarotenic Acid Sulfoxide (m/z 340.3), 
Hydroxy-Tazarotenic Acid (m/z 340.3) and Tazarotenic Acid Sulfone (m/z 356.3) 
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Figure 9-10.  MS/MS fragmentation pattern for tazarotenic acid and metabolites. 
Corresponding Fragmentation Pattern For Tazarotenic Acid (m/z 324.2), Tazarotenic Acid 
Sulfoxide (m/z 340.3), Hydroxytazarotenic Acid (m/z 340.3) and Tazarotenic Acid Sulfone (m/z 
356.3) 
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Figure 9-11.  Proposed metabolic scheme of tazarotenic acid by CYP26A1 and CYP26B1. 
CYP26A1 or CYP26B1 contributes to each of the metabolic steps identified in the metabolism of 
tazarotenic acid.   
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Figure 9-12.  Enzyme kinetic plots for the formation of tazarotenic acid sulfoxide and 
hydroxytazarotenic acid by CYP26A1 (circles) and CYP26B1 (squares). 
Formation was characterized by Michaelis-Menten kinetics with CYP26B1 having kcat values 
that were approximately 1.3 – 1.6-fold higher than those observed for CYP26A1. 
 
 
Table 9-3.  Enzyme kinetic parameters for NADPH-dependent metabolism of tazarotenic 
acid to tazarotenic acid sulfoxide and hydroxytazarotenic acid (95% confidence interval 
is shown in parentheses). 
 CYP26A1 CYP26B1  
Metabolite 
Km 
(µM) 
Clint 
(mL/min/nmol) 
Km 
(µM) 
Clint 
(mL/min/nmol) 
kcat,B1  
 kcat,A1 
TA-Sulfoxide 
0.24 
(0.18 – 0.27) 
1.03 
(0.87 – 1.18) 
1.01 
(0.85 – 1.18) 
0.38 
(0.34 – 0.44) 
1.60 
(1.52 – 1.68) 
Hydroxy-TA
*
 
0.39 
(0.31 – 0.42) 
4.01 
(3.52 – 4.48) 
0.56 
(0.42 – 0.63) 
3.67 
(3.22 – 4.14) 
1.32 
(1.27 – 1.37) 
 
*
 Metabolite Standard not available; Concentrations based on tazarotenic acid sulfoxide standard curve 
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9.3.4. Tazarotenic Acid Phenotyping.   
Previous reports evaluating the enzymes responsible for tazarotenic acid metabolism in vitro 
have implicated CYP2C8, FMO1 and FMO3 in the formation of tazarotenic acid sulfoxide (Attar 
et al., 2003).  Using an expanded drug metabolizing enzyme panel and clinically relevant 
concentrations of tazarotenic acid, additional enzymes were identified that may contribute to the 
metabolism of tazarotenic acid.  The highest rates of tazarotenic acid sulfoxide formation were 
observed for CYP26A1 and CYP26B1, followed by CYP2C8 and CYP3A7 (Figure 9-13A).  
Formation of the sulfoxide metabolite was also observed in incubations with CYP2C9, CYP2J2, 
CYP3A4, CYP3A5 and aldehyde oxidase.  Minor contributions were noted for CYP1A2 and 
CYP2B6.  No metabolite formation was observed in incubations with FMO1, FMO3 or FMO5.  
The hydroxylated metabolite of tazarotenic acid was formed primarily by CYP26A1 and 
CYP26B1, with additional contributions from CYP2C8, CYP3A5 and CYP3A7 (Figure 9-13B).  
Similar to the formation of tazarotenic acid sulfoxide, trace amounts of the hydroxylated 
metabolite were also observed in incubations with the majority of the enzymes evaluated in the 
panel. 
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Figure 9-13.  Formation of tazarotenic acid sulfoxide and hydroxytazarotenic acid in a 
panel of recombinant enzymes. 
Formation of both enzymes was predominantly catalyzed by CYP26A1 and CYP26B1 with 
additional contributions from CYP3A and CYP2C isozymes.   
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9.4. Discussion 
The CYP26 family of cytochrome P450s (CYP26A1, CYP26B1 and CYP26C1) has been 
identified as being responsible for the metabolism of at-RA and its metabolites (Ray et al., 1997; 
Taimi et al., 2004; Guengerich, 2006; Lee et al., 2007; Lutz et al., 2009; Thatcher and 
Isoherranen, 2009; Helvig et al., 2011; Ross and Zolfaghari, 2011; Nelson et al., 2013a).  To 
date, however, no known xenobiotic compounds have been identified as substrates of 
CYP26A1 or CYP26B1, the two most characterized CYP26 isoforms.  As both enzymes are 
expressed in human skin and many retinoid-based treatments are administered topically, the 
potential exists for these CYP26s to contribute to the metabolism and elimination of these 
compounds (Heise et al., 2006; Osanai and Lee, 2011; Topletz et al., 2012).  Furthermore, 
a major focal point in the development of synthetic retinoids is to overcome the pharmacokinetic 
shortcomings of at-RA, such as the observed autoinduction of its clearance pathways.  
Tazarotene is an acetylenic retinoid which is readily converted via hydrolysis to tazarotenic acid 
upon topical administration (Duvic, 1997; Madhu et al., 1997; Tang-Liu et al., 1999; Menter, 
2000; Yu et al., 2003; Attar et al., 2005; Talpur et al., 2009).  It is prescribed for the treatment of 
abnormal keratinocyte proliferation, as is observed in patients with stable plaque psoriasis, mild 
to moderate acne and basal cell carcinoma (Tang-Liu et al., 1999; Talpur et al., 2009).  The 
pharmacological mechanism of action described for tazarotene involves metabolism to 
tazarotenic acid which subsequently binds to retinoic acid receptors, primarily RAR-β and RAR-
γ (Chandraratna, 1996).  As an inhibitor of CYP26A1 and CYP26B1, tazarotenic acid may also 
serve to locally increase concentrations of retinoic acid in the skin, a mechanism that may hold 
potential in treating dermatological disorders.  As such, a greater understanding of the structural 
characteristics of CYP26A1 and CYP26B1 which lend themselves to the catalytic and inhibitory 
properties of tazarotenic acid by these enzymes may have significant clinical relevance in terms 
of developing the next generation of topical pharmaceutics.   
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Homology models were designed in order to characterize the active site and substrate 
binding characteristics of CYP26A1 and CYP26B1.  Prior to designing the homology models, 
the wild type gene sequence of CYP26B1 was verified from a panel of human livers as the initial 
clone differed in two amino acid residues from the currently available sequence of the enzyme 
(NCBI Reference Sequence: NP_063938.1; UniProtKB Q9NR63), which had been isolated from 
human retinal cDNA(White et al., 2000).  Consistent with the commercially available clone, the 
amino acid sequence analysis showed that the amino acids residues at position 64 and 260 in 
the CYP26B1 sequence are an arginine and a serine residue, respectively, as opposed to the 
histidine and glycine originally reported from the retinal cDNA of a single human donor (Figure 
9-1).  However, as neither of these residues appears to be involved in substrate binding, it is 
unlikely that they influenced the results of previously published CYP26B1 homology models 
(Karlsson et al., 2008; Saenz-Mendez et al., 2012).  Estimates of the active site volume for 
CYP26A1 (918 Å3) and CYP26B1 (977 Å3), suggest that each enzyme can bind ligands such as 
at-RA and tazarotenic acid with molecular volumes of approximately 300 Å3 as well as much 
larger ligands, similar to the ligand binding profiles of other cytochrome P450 enzymes.  
Structural comparison of the two homology models suggests that selectivity between CYP26A1 
and CYP26B1 may be dependent upon interactions with acidic binding residues as the active 
site amino acids involved in enzyme-ligand hydrophobic interactions appear to be fairly well 
conserved between the two enzymes (Figure 9-3).   
The importance of being able to corroborate homology model data with supporting “site-
of-metabolism” data cannot be understated.  While successfully predicting the ability of an 
enzyme to bind an inhibitor suggests that the general active site characteristics of the homology 
model are representative of the actual enzyme, being able to predict the correct orientation of 
the ligand within the active site of the enzyme imparts an additional level of rigor to the 
homology model.  As an initial attempt to validate the homology models, at-RA was docked into 
the active sites of CYP26A1 and CYP26B1.  The mechanism for the formation of 4-
63 
 
hydroxyretinoic acid by CYP26A1 and CYP26B1 involves hydrogen atom abstraction at a pro-
chiral center, resulting in formation of either 4-(S)- or 4-(R)-at-RA.    Previous in vitro data 
suggests that CYP26A1 preferentially catalyzes the stereoselective metabolism of at-RA to 4-
(S)-hydroxy-at-RA while CYP26B1 catalyzes the formation of both 4-hydroxy-at-RA 
enantiomers, results which have also been rationalized through homology modeling of 
CYP26A1(Shimshoni et al., 2012; Topletz, 2013).  In the case of the CYP26A1 homology model 
presented in this manuscript, all docking attempts resulted in the hydrogen atom leading to 
formation of 4-(S)-hydroxy-at-RA being oriented toward the heme, with the model unable to 
orient at-RA in the active site of CYP26A1 in a manner conducive with formation of 4-(R)-
hydroxy-at-RA.  Conversely, when at-RA was docked into the active site of CYP26B1 docking 
poses with either hydrogen atom at the 4-position toward the heme iron were observed.  Taken 
together, this validation of the stereoselective metabolism of at-RA by the homology models 
suggests that the critical structural differences between the two enzymes which impart the 
stereoselective properties of at-RA metabolism by CYP26A1 and CYP26B1 are sufficiently 
captured by the models.   
To apply the model to a xenobiotic ligand, the sites of metabolism of tazarotenic acid, an 
inhibitor of CYP26, were predicted.  When tazarotenic acid was docked in the active sites of 
CYP26A1 or CYP26B1, a single orientation was observed with the benzothiopyranyl moiety 
directed toward the heme (Figure 9-6A and 9-6C).  A number of the residues that appear to be 
important in orienting tazarotenic acid in the active sites of CYP26A1 and CYP26B1 have also 
been reported to be involved in the binding of at-RA in the active sites of these enzymes.  For 
example, Trp112, Phe222, Phe299, Thr304, Pro369 and Val370 have been proposed to be 
involved in CYP26A1 binding of both at-RA as well as retinoic acid metabolism blocking agents 
(RAMBAs) that are able to inhibit the activity of CYP26A1 (Gomaa et al., 2008; Karlsson et al., 
2008; Gomaa et al., 2011a; Gomaa et al., 2011b).  Similarly, Trp65, Trp117, Thr121, Phe222, 
Phe295, Ser369, Val370 and Pro371 have been suggested to be key residues in binding at-RA 
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and other ligands of CYP26B1 (Karlsson et al., 2008; Saenz-Mendez et al., 2012).  Results from 
metabolite identification studies confirmed the ability of CYP26A1 and CYP26B1 to contribute to 
the metabolism of tazarotenic acid and tazarotenic acid sulfoxide only at the benzothiopyranyl 
end of the molecule, and a proposed metabolic scheme is shown in Figure 9-11.  Enzyme 
kinetic experiments suggest that the metabolism of tazarotenic acid by CYP26A1 and CYP26B1 
represents a rare example of a substrate having higher kcat values for CYP26B1 as compared to 
CYP26A1. 
Finally, previously reported efforts to identify the enzymes responsible for the 
metabolism of tazarotenic acid have implicated CYP2C8, FMO1 and FMO3 in the metabolism of 
tazarotenic acid to a sulfoxide metabolite (Attar et al., 2003).  As recent literature reports have 
highlighted the importance of conducting reaction phenotyping experiments at clinically relevant 
concentrations (Filppula et al., 2011; VandenBrink et al., 2011; Karonen et al., 2012), we have 
re-evaluated the enzymatic pathways responsible for the metabolism of tazarotenic acid.  When 
reaction phenotyping experiments were conducted at the clinically relevant concentration of 100 
nM, CYP26A1 and CYP26B1 were identified as the major cytochrome P450 isoforms involved 
in the formation of tazarotenic acid sulfoxide and hydroxytazarotenic acid in vitro (Figure 9-13).  
Other enzymes that contributed to the formation of the sulfoxide metabolite included CYP2C8, 
CYP2C9, CYP2J2, CYP3A4, CYP3A5 and CYP3A7 and aldehyde oxidase, though metabolite 
formation rates by the CYP26 isoforms were at least 2.5-fold higher than those observed for any 
other cytochrome P450 enzymes.  No formation of the sulfoxide by FMO1, FMO3 or FMO5 was 
observed, suggesting that these enzymes do not play a role in the formation of the metabolite at 
sub-micromolar concentrations of tazarotenic acid.   
To our knowledge, this manuscript describes the first known homology models of 
CYP26A1 and CYP26B1 that incorporate metabolic data from both endogenous and xenobiotic 
substrates.  It also details the first known contributions of the CYP26 family of cytochrome P450 
enzymes to the metabolism of a xenobiotic compound and provides additional computational 
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analyses of the active sites characteristics of each enzyme.  Analysis of the active site features 
of the CYP26A1 and CYP26B1 homology models suggests that the greatest site of structural 
divergence is in the carboxylate-binding region of the active site and that the enzymes may be 
capable of binding much larger ligands as well, similar to other drug metabolizing cytochrome 
P450 enzymes.  Further understanding of the active site characteristics of CYP26A1 and 
CYP26B1 which play a role in their substrate binding properties should serve to increase the 
likelihood of identifying CYP26-selective inhibitors that may ultimately prove useful in the 
treatment of various disease states.   
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10. Chapter III:  Comparison of the Ligand Binding Site of CYP2C8 with CYP26A1 and 
CYP26B1: A Structural Basis for the Identification of New Inhibitors of the Retinoic Acid 
Hydroxylases 
Accepted for Publication:  Journal of Enzyme Inhibition and Medicinal Chemistry, 2016. 
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10.1. Introduction 
 Endogenous retinoic acid concentrations are highly regulated owing to their importance 
in cellular development with altered concentrations of retinoic acid known to have 
pharmacological and toxicological implications (Lotan, 1980; Sporn and Roberts, 1984; 
McCaffery and Drager, 2000; Ross et al., 2000; Clagett-Dame and DeLuca, 2002; Maden, 
2002).  In humans, retinoic acid binds to the retinoic acid and retinoid X receptors and plays a 
key role in the regulation of genes that affect the extent of cellular proliferation and 
differentiation as well as apoptosis (Levin et al., 1992; Mangelsdorf et al., 1992; Mark et al., 
2006; Altucci et al., 2007; di Masi et al., 2015).  The regulation of circulating retinoic acid 
concentrations can occur through modulation of its synthesis, which involves multiple enzymatic 
steps in the conversion of retinol to all-trans-retinoic acid (at-RA) or through its clearance, which 
is primarily mediated by cytochrome P450-catalyzed oxidation to 4-hydroxy-at-retinoic acid 
(Duester, 2008; Niederreither and Dolle, 2008).  Within the cytochrome P450 superfamily of 
xenobiotic metabolizing enzymes, the CYP26 subfamily (CYP26A1, CYP26B1 and CYP26C1) 
are the primary enzymes involved in retinoic acid metabolism (Ray et al., 1997; Lutz et al., 
2009; Thatcher and Isoherranen, 2009; Thatcher et al., 2010; Ross and Zolfaghari, 2011).  
While hepatic CYP26 content is primarily a function of CYP26A1 expression, CYP26A1 and 
CYP26B1 mRNA are ubiquitously expressed, with sites of expression including the skin, lungs, 
testes and brain (Ray et al., 1997; White et al., 2000; Wang et al., 2002; Xi and Yang, 2008; Tay 
et al., 2010; Thatcher et al., 2010; Topletz et al., 2012; Nelson et al., 2013a).  Less information 
is available about the expression patterns and functional relevance of CYP26C1.   
 A significant amount of catalytic overlap is observed for CYP26A1 and CYP26B1 in 
regard to their metabolism of at-RA, though the sequence homology between the two isozymes 
is only 42% (Taimi et al., 2004; Topletz et al., 2012; Nelson et al., 2013a).  Perhaps owing to 
their homeostatic role in the regulation of retinoic acid concentrations and the subsequent 
pharmacological or toxicological outcomes, the pursuit of selective chemical inhibitors of 
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CYP26A1 or CYP26B1 has received interest in both the inflammation and oncology therapeutic 
areas (Miller, 1998; Kuenzli and Saurat, 2001; Njar, 2002; Ahmad and Mukhtar, 2004; Njar et 
al., 2006; Verfaille et al., 2008).  Many of the compounds designed to inhibit CYP26 activity, 
also known as retinoic acid metabolism blocking agents (RAMBAs), share a similar 
pharmacophore, with an extended hydrophobic region that bridges a hydrophobic or aromatic 
ring system on one end of the molecule to a hydrogen bond accepting group on the opposite 
end (Purushottamachar et al., 2012; Sun et al., 2015).  In many cases, the aromatic group 
described above is an azole-containing ring system, designed to coordinate to the porphyrin iron 
of CYP26A1 or CYP26B1 and thus inhibit the enzyme (Njar, 2002; Njar et al., 2006; Gomaa et 
al., 2008; Gomaa et al., 2011a; Thatcher et al., 2011; Nelson et al., 2013a).  Liarazole currently 
represents the most studied example of a RAMBA in clinical use (De Coster et al., 1992; Njar et 
al., 2006).   
 Approximately 5% to 8% of xenobiotic metabolism has been attributed to CYP2C8, with 
highly characterized substrates including amodiaquine, repaglinide, rosiglitazone, cerivastatin, 
paclitaxel and montelukast (Totah and Rettie, 2005; Lai et al., 2009; VandenBrink et al., 2011; 
Karonen et al., 2012).  CYP2C8 has also been shown to metabolize at-RA, 9-cis-retinoic acid 
and 13-cis-retinoic acid (Nadin and Murray, 1999; McSorley and Daly, 2000; Marill et al., 2002; 
Marill et al., 2003; Rowbotham et al., 2010).  Potent in vitro inhibitors of CYP2C8-catalyzed 
metabolism include montelukast (both substrate and inhibitor), candesartan cilexetil, zafirlukast, 
clotrimazole and fluconazole (Walsky et al., 2005; Nath et al., 2010; VandenBrink et al., 2011).  
Clinically relevant drug interactions attributed to CYP2C8 inhibition have been noted for 
rosiglitazone, repaglinide and cerivastatin when co-administered with the CYP2C8 inhibitor 
gemfibrozil (Backman et al., 2002; Niemi et al., 2003; Tornio et al., 2008; Honkalammi et al., 
2011).  The active site properties of CYP2C8 which contribute to its substrate and inhibitor 
profiles are fairly well understood, with the crystal structure of CYP2C8 having been solved with 
various ligands bound in the active site, including 9-cis-retinoic acid (Schoch et al., 2004).  The 
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active site volume of CYP2C8 is relatively large (1438 Å3) and it has been described as having a 
bifurcated Y-shaped geometry (Schoch et al., 2004; Schoch et al., 2008).  Similar to the ligand 
profile of CYP26s, early pharmacophore models of CYP2C8 ligands suggested the need for a 
hydrophobic or aromatic group proximal to the site of oxidation, an extended hydrophobic chain 
distal to the site of oxidation and multiple hydrogen binding sites, properties which are often 
displayed by various retinoid or retinoid-like compounds (Kerdpin et al., 2004; Melet et al., 2004; 
Schoch et al., 2008; Lai et al., 2009).   
 Owing to the similar pharmacophore features described for CYP2C8 and CYP26 and as 
CYP2C8 has also been shown to catalyze the formation of 4-hydroxyretinoic acid from at-RA, 
the potential exists for the inhibitor binding profile of CYP26A1 and CYP26B1 to overlap with 
that of CYP2C8.  As such, the primary aim of this work was to evaluate the potential for known 
inhibitors of CYP2C8 to inhibit CYP26A1 or CYP26B1 activity.  In vitro inhibition assays were 
used to determine IC50 values for a set of known CYP2C8 inhibitors against CYP26A1 and 
CYP26B1.  In the process, the use of tazarotenic acid, which has recently been shown to be 
metabolized by CYP26A1 and CYP26B1, as a probe substrate for CYP26 inhibition assays was 
evaluated.  The mechanism of active site binding and inhibition of CYP26A1 and CYP26B1 was 
then characterized for compounds with azole moieties as well as those hypothesized to not 
inhibit the enzymes through type II binding interactions.  Finally, in vitro inhibition parameters 
were compared to reported skin or plasma concentrations following clinically relevant doses of 
CYP2C8 inhibitors in an attempt to estimate the magnitude of the potential clinical interaction of 
known CYP2C8 inhibitors on CYP26 activity in vivo.   
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10.2. Materials and Methods. 
10.2.1. Materials.   
CYP26A1 and CYP26B1 were generous gifts from Dr. Nina Isoherranen (University of 
Washington).  Recombinant CYP2C8 Supersomes® and purified human cytochrome P450 
reductase were obtained from Corning Life Sciences (Tewksbury, MA).  Tazarotenic acid, 
MM11253, liarazole, EC23, AM80 and candesartan were purchased from Tocris Chemicals 
(Bristol, United Kingdom).  Montelukast, pioglitazone, rosiglitazone and zafirlukast were from 
Cayman Chemical (Ann Arbor, MI).  Talarazole was purchased from MedChem Express 
(Monmouth Junction, NJ).  Rapid equilibrium dialysis (RED) device kits were obtained from 
ThermoFisher Scientific (Waltham, MA).  All other chemicals were from Sigma-Aldrich (St. 
Louis, MO) and were of the highest grade available.   
10.2.2. Homology Modeling and Computational Docking Simulations.   
CYP26A1 and CYP26B1 homology models based on the crystal structure of CYP120 (pdb 
2VE3) were designed using Prime modeling software (Schrodinger LLC, New York) as 
previously described (Foti et al., 2016). The crystal structure of CYP2C8 was obtained from the 
RCSB Protein Data Bank (pdb 1PQ2).  The CYP26A1 or CYP26B1 homology models were 
superimposed on the CYP2C8 crystal structure using the Super script within Pymol 
(Schrodinger LLC, New York; http://www.pymolwiki.org/index.php/Super).  Structural similarity 
was determined by calculating the root mean square deviation (RMSD) between the protein 
structures.  Amino acid residues 494 – 512 from the CYP26B1 homology model were not 
included in the RMSD calculation.  Computational docking of clotrimazole (CYP26A1 and 
CYP26B1), zafirlukast (CYP26A1) or candesartan cilexetil (CYP26B1) was accomplished using 
an induced fit docking algorithm which incorporated decreased van der Waals radii, spatial 
repositioning of non-rigid protein side chains and additional energy minimization functions post-
ligand docking (Sherman et al., 2006a; Sherman et al., 2006b).  Compounds for docking 
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simulations were chosen based on inhibition potency as well as their potential (or lack thereof) 
for type II azole-heme interactions.  Docking parameters required the center of mass of the 
inhibitors to be positioned within a 1728 Å3 grid which was designed to be approximately 3 Å 
above the protoporphyrin ring system using Glide (Schrodinger LLC, New York).  The 
OPLS_2005 force field constraints used by LigPrep (Schrodinger LLC, New York) were used to 
prepare the energy minimized structures of clotrimazole (hypothesized to bind through type II 
ligand interactions) and candesartan cilexetil and zafirlukast (two compounds not hypothesized 
to interaction through type II binding) prior to docking.   Binding orientations obtained from the 
computational docking experiments were evaluated and scored using GlideScore and eModel, 
which incorporates aspects of the GlideScore, ligand score and grid score into the final 
assessment of the plausibility of the docking results.   
10.2.3. In Vitro Inhibition Assays.   
CYP2C8 in vitro IC50 values were obtained from previously reported literature sources and are 
noted in Table 10-1 (Walsky et al., 2005; Nath et al., 2010; VandenBrink et al., 2011).  An initial 
single point inhibition screen (n = 3) was then used to estimate the inhibition potency of the set 
of known CYP2C8 inhibitors against CYP26A1 or CYP26B1. Talarazole and AM80 were 
included in the screening set as positive controls for CYP26 inhibition.  In vitro screening 
conditions consisted of 10 µM inhibitor, 5 nM CYP26A1 or CYP26B1, 25 nM purified human 
cytochrome P450 reductase, and 200 nM tazarotenic acid, a compound which has recently 
been shown to be a substrate of CYP26 (Foti et al., 2016).  The final volume of the incubation 
was 50 µL.  Screening incubations were performed in triplicate and were pre-warmed at 37ºC 
for 3 minutes prior to addition of 1 mM NADPH (final concentration).  Incubations were 
terminated after 10 minutes with three volumes (v/v) of 100 nM tolbutamide in acetonitrile and 
centrifuged for 20 minutes at 1240 x g.  A portion of the resulting supernatant was transferred 
for liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis. 
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Table 10-1.  Previously published CYP2C8 IC50 values ± standard error.  All IC50 values 
were determined using recombinant CYP2C8 enzymes except where noted.  (N.R. = Not 
Reported). 
Inhibitor 
CYP2C8 IC50 
(µM) 
Probe Substrate Reference 
Benzbromarone 0.38 (N.R.) Montelukast (HLM) VandenBrink et al., 2011 
Candesartan 36.2 ± 1.7 Amodiaquine Walsky et al., 2005 
Candesartan Cilexetil 0.496 ± 0.190 Amodiaquine Walsky et al., 2005 
Clotrimazole 0.725 ± 0.116 Amodiaquine Walsky et al., 2005 
17α-Ethynylestradiol 6.54 ± 1.22 Amodiaquine Walsky et al., 2005 
Fluconazole 48.9 (N.R.) Amodiaquine Nath et al., 2010 
Itraconazole 2.16 ± 0.41 Paclitaxel Unpublished Data 
Mometasone 0.813 ± 0.112 Amodiaquine Walsky et al., 2005 
Montelukast 0.00922 ± 0.00088 Amodiaquine Walsky et al., 2005 
Pioglitazone 11.7 ± 4.0 Amodiaquine Walsky et al., 2005 
Quercetin 3.94 ± 0.64 Amodiaquine Walsky et al., 2005 
Raloxifene 2.15 ± 0.90 Amodiaquine Walsky et al., 2005 
Repaglinide 11.1 (N.R.) Montelukast (HLM) VandenBrink et al., 2011 
Ritonavir 3.03 ± 1.14 Amodiaquine Walsky et al., 2005 
Rosiglitazone 10.8 ± 3.1 Amodiaquine Walsky et al., 2005 
Tamoxifen 3.34 ± 1.55 Amodiaquine Walsky et al., 2005 
Zafirlukast 0.644 ± 0.273 Amodiaquine Walsky et al., 2005 
 
 IC50 values were then determined for compounds exhibiting greater than 50% inhibition 
in the screening assay for at least one of the CYP26 isoforms.  Incubations conditions (n = 3) 
were similar to those used in the screening assay except for the inhibition concentrations, which 
ranged from 0 – 100 µM. CYP26A1 and CYP26B1 IC50 values were estimated using a three 
parameter inhibition model as shown in Equation 1, where Activitymax represents the observed 
probe substrate activity with no inhibitor, Activitymin is the probe substrate activity at the 
maximum inhibitor concentration and [I] is the concentration of inhibitor in the incubation.  IC50 
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incubations were performed in triplicate.  The organic content of each incubation was kept to 
less than 1% of the total volume and product formation under the conditions described above 
had previously been determined to be linear with respect to incubation time and protein content.   
 
Equation 1  % 𝑅𝑒𝑚𝑎𝑖𝑛𝑖𝑛𝑔 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦𝑚𝑖𝑛 +
𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 𝑚𝑎𝑥−𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦𝑚𝑖𝑛
1+10(𝑙𝑜𝑔 [𝐼]−𝑙𝑜𝑔𝐼𝐶50)
 
  
10.2.4. Spectral Binding Determination.   
Spectral binding characterizations (n = 3) were carried out to determine the binding orientation 
of the most potent azole-containing compound (clotrimazole) for CYP26A1 and CYP26B1, as 
well as zafirlukast (CYP26A1) and candesartan cilexetil (CYP26B1).  The binding of 
clotrimazole to CYP2C8 was also explored.  Ligand concentrations ranged from 0 – 20 µM.  A 
protein concentration of 500 nM was used in spectral binding assays.  Following each addition 
of ligand, cuvettes (1 cm path length) were inverted multiple times and allowed to settle for 1 
minute prior to measuring the difference spectra from 350 – 550 nm using a Cary 4000 UV-Vis 
spectrophotometer (Agilent Technologies, Santa Clara, CA).  Spectral binding constants (Ks) 
were estimated using nonlinear regression of the absorbance difference (ΔAbs) for each 
enzyme (CYP26A1, λ430nm – λ413nm; CYP26B1, λ430nm – λ400nm; CYP2C8, λ430nm – λ390nm) as shown 
in Equation 2. 
 
Equation 2     ∆𝐴𝑏𝑠 =  
[𝑆] ∗ ∆𝐴𝑏𝑠𝑚𝑎𝑥
[𝑆]+𝐾𝑠
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10.2.5. Assessment of In Vitro Free Fraction.   
In order to determine the unbound fraction of clotrimazole in the IC50 and spectral binding 
assays, equilibrium dialysis was conducted under relevant conditions.  Experiments were 
performed in triplicate using the Rapid Equilibrium Dialysis Device (Thermo Fisher Scientific, 
Waltham, MA) which was prepared according to the manufacturer’s recommendations.  In brief, 
1 µM of clotrimazole was added to 5 nM or 500 nM CYP26A1 or CYP26B1 in potassium 
phosphate buffer (100 µL, pH 7.4) and was dialyzed for 12 hours at 37 ºC against 300 µL of 
control potassium phosphate buffer.  The plate was agitated using an orbital shaker set to 200 
rpm.  Upon completion of the incubation period, a 50 µL aliquot was removed from each side of 
the equilibrium dialysis membrane and added to 50 µL of control enzyme or buffer to normalize 
for potential matrix effects.  Protein precipitation was achieved by adding three volumes of 100 
nM tolbutamide in ice cold acetonitrile and centrifuging the samples for 20 minutes at 1240 x g.  
A portion of the resulting supernatant was transferred for liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) analysis.  The unbound fraction was determined as shown in 
Equation 3. 
 
Equation 3  𝑓𝑢 =
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝐵𝑢𝑓𝑓𝑒𝑟 𝐶ℎ𝑎𝑚𝑏𝑒𝑟
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑖𝑛 𝑆𝑎𝑚𝑝𝑙𝑒 𝐶ℎ𝑎𝑚𝑏𝑒𝑟
 
 
10.2.6. In Vitro Stability of Candesartan Cilexetil.   
Candesartan is the pharmacologically active form of the prodrug candesartan celexetil, which is 
hydrolyzed by intestinal esterases following oral administration (Gleiter and Morike, 2002).  In 
order to determine whether the observed inhibition potency of candesartan cilexetil was due to 
the prodrug or to the hydrolysis product, the in vitro stability of candesartan cilexetil was 
determined using CYP26A1, CYP26B1 and CYP2C8.  Briefly, 1 µM candesartan cilexetil was 
added to incubations containing 5 nM CYP26A1, CYP26B1 or CYP2C8 and 25 nM purified 
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human cytochrome P450 reductase in 100 mM potassium phosphate buffer (pH 7.4; n = 3).  
Incubations were performed at 37 ºC and initiated through addition of 1 mM NADPH (final 
concentration) in order to mirror the conditions of the IC50 assay.  Aliquots were removed at 0, 1, 
5 and 10 minutes and immediately placed into ice cold acetonitrile containing 100 nM 
tolbutamide as an internal standard.  Samples were vortex-mixed and centrifuged for 20 
minutes at 1240 x g.  A portion of the supernatant was transferred for LC-MS/MS analysis of 
candesartan cilexetil degradation and candesartan formation in the incubations.   
 
10.2.7. Calculation of Cmax,u / IC50.  
 Previously reported Cmax and unbound fraction values in plasma were obtained for 17 known 
inhibitors of CYP2C8 (benzbromarone, candesartan, candesartan cilexetil, clotrimazole, 17α-
ethynylestradiol, fluconazole, itraconazole, mometasone furoate, montelukast, pioglitazone, 
quercetin, raloxifene, repaglinide, ritonavir, rosiglitazone, tamoxifen and zafirlukast) at clinically 
relevant doses (http://www.drugbank.ca/; Walter-Sack et al., 1988; Saperstein et al., 1989; 
Boulton et al., 1998; Daley-Yates et al., 2004; Goodman and Gilman, 2006; Moon et al., 2008; 
Uchida et al., 2010; Karonen et al., 2011; Deshpande, 2013).  As no reported plasma 
concentrations of clotrimazole after oral administration were available, skin concentrations 
following a topical administration were used.  The ratio of the unbound Cmax values to the in vitro 
IC50 values was calculated using Equation 4. 
 
Equation 4  
𝐶𝑚𝑎𝑥,𝑢𝑛𝑏𝑜𝑢𝑛𝑑
𝐼𝐶50
=
𝐶𝑚𝑎𝑥∗𝑓𝑢,𝑝𝑙𝑎𝑠𝑚𝑎
𝐼𝐶50
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10.2.8. Liquid Chromatography – Mass Spectrometry Analysis.   
Tazarotenic acid sulfoxide, clotrimazole, candesartan and candesartan cilexetil was monitored 
using LC-MS/MS.  The mass spectrometer incorporated electrospray ionization coupled to an 
Applied Biosystems 4000 QTrap (Applied Biosystems, Foster City, CA).  Samples were injected 
(10 µL) using a LEAP CTC HTS PAL autosampler (CTC Analytics, Carrboro, NC) and 
introduced to the mass spectrometer using two LC-20AD binary pumps with an in-line DGU-
20A5 solvent degasser (Shimadzu, Columbia, MD).  A rapid gradient using 0.1% formic acid 
(v/v) in water (A) and 0.1% formic acid in methanol:acetonitrile (1:1; B) with a Synergi 2.5 µm 
Hydro RP 100 Å (50 x 2.0 mm) column (Phenomenex, Torrance, CA) was utilized.  Gradient 
conditions were as follows: 2.0% B (0 – 0.2 minutes), 2.0% B – 95% B (from 0.2 – 1.0 minutes), 
95% B (from 1.0 – 1.5 minutes) and re-equilibration at 2.0% B for 0.3 minutes.  Tazarotenic acid 
sulfoxide (positive ion, 340.3 / 280.3) clotrimazole (positive ion, 345.4 / 277.0), candesartan 
(positive ion, 441.0 / 263.1), candesartan cilexetil (positive ion, 611.1 / 567.2) and the internal 
standard tolbutamide (positive ion, 271.2 / 91.1; negative ion, 268.9 / 169.7) were detected 
under MRM (multiple reaction monitoring) conditions. Additional parameters that were used in 
the tazarotenic acid analytical method included the source temperature (500 °C), curtain gas (12 
arbitrary units), ion spray voltage (5000 V), CAD gas (medium), and ion source gas 1 and gas 2 
(30 arbitrary units, each).   
 
 
 
 
 
78 
 
10.3. Results 
10.3.1. Evaluation of tazarotenic acid sulfoxide formation as a probe substrate of CYP26.   
Tazarotenic acid (Figure 10-1) has recently been identified as a xenobiotic substrate of 
CYP26A1 and CYP26B1 (Foti et al., 2016).  Prior to utilizing the tazarotenic acid assay to 
screen new compounds for inhibition of CYP26A1 and CYP26B1, IC50 values were generated 
for a test set of known CYP26 inhibitors using tazarotenic acid as the probe substrate and 
compared to previously published results obtained when 9-cis-retinoic acid was the probe 
substrate (Table 10-2).   Inhibitor potency rankings were generally the same and a statistically 
significant correlation was observed between the IC50 values obtained using the two assays.  
Correlation coefficients (r2) for the IC50 values obtained using tazarotenic acid assay and the 9-
cis-retinoic acid assay were 0.78 and 0.62 for CYP26A1 and CYP26B1, respectively, 
suggesting that formation of tazarotenic acid sulfoxide is an appropriate probe reaction for 
determining inhibition of CYP26 activity (Figure 10-2).   
 
 
Figure 10-1.  CYP26-catalyzed metabolism of tazarotenic acid to tazarotenic acid 
sulfoxide. 
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Table 10-2.  Inhibition of tazarotenic acid sulfoxide formation in recombinant CYP26 
enzymes by known inhibitors of retinoic acid hydroxylation. 
Values in parenthesis represent the 95% confidence intervals for the nonlinear regression 
calculations, except for ketoconazole and liarazole with 9-cis-retionic acid, where standard error 
values were reported (Thatcher et al., 2011; Buttrick, 2012).  (N.R. = Not Reported).   
 
 IC50 (µM) 
 CYP26A1 CYP26B1 
Inhibitor 
Tazarotenic 
Acid 
9-cis-Retinoic 
Acid 
Tazarotenic 
Acid 
9-cis-Retinoic 
Acid 
CD437 
0.01 
(0.01-0.03) 
0.04 
(N.R.) 
0.14 
(0.09-0.22) 
0.03 
(N.R.) 
MM11253 
0.02 
(0.01-0.03) 
0.06 
(N.R.) 
1.25 
(0.81-1.91) 
1.03 
(N.R.) 
Talarazole 
0.02 
(0.01-0.04) 
0.005 
(0.003-0.007) 
0.001 
(0.001-0.002) 
0.0005 
(0.00007-0.0009) 
Ketoconazole 
0.13 
(0.05-0.31) 
0.55 
(1.3)* 
0.19 
(0.06-0.42) 
0.14 
(0.03-0.56) 
SR11237 
0.81 
(0.34-1.91) 
3.3 
(N.R.) 
6.86 
(3.12-14.2) 
14.2 
(N.R.) 
Liarazole 
0.84 
(0.31-2.48) 
2.1 
(1.1)* 
0.01 
(0.01-0.03) 
0.02 
(0.013-0.027) 
Bexarotene 
1.31 
(0.54-4.22) 
12.3 
(N.R.) 
1.60 
(0.42-6.07) 
4.0 
(N.R.) 
EC23 
1.60 
(0.61-4.94) 
8.3 
(4.0-17) 
3.45 
(1.47-8.44) 
0.94 
(0.44-2.0) 
AM80 
2.89 
(1.52-7.43) 
12 
(8.1-18) 
9.21 
(3.69-24.2) 
6.6 
(2.3-19) 
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Figure 10-2.  Correlation between tazarotenic acid and 9-cis-retinoic acid derived IC50s. 
Correlation between previously reported CYP26 IC50 values using 9-cis-retinoic acid as a probe 
substrate and IC50 values generated using tazarotenic acid as a probe substrate for for 
CYP26A1 (r2 = 0.78) or CYP26B1 (r2 = 0.62) in vitro activity in recombinant CYP enzymes.  
Lines represent unity (solid black), 3-fold difference (dotted red) and 10-fold difference (dotted 
black).   
 
10.3.2. In Vitro Inhibition Screening and IC50 Determination.   
An initial set of 29 known CYP2C8 inhibitors was screened for inhibition of CYP26A1- or 
CYP26B1-catalyzed tazarotenic acid sulfoxide formation using a single inhibitor concentration 
(10 µM).  Inhibition values ranged from no inhibition to greater than 90% inhibition (Figure 10-3).  
IC50 values were determined for 17 compounds which exhibited greater than 50% inhibition in 
the single concentration inhibition screen for either CYP26A1 or CYP26B1.  Clotrimazole was 
the most potent inhibitor of CYP26 activity with IC50 values of 20 nM and 50 nM for CYP26A1 
and CYP26B1, respectively (Table 10-3; Figure 10-4).  The most potent inhibitors hypothesized 
to not inhibit through type II azole-heme interactions were zafirlukast for CYP26A1 (IC50 = 60 
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nM) and candesartan cilexetil for CYP26B1 (IC50 = 270 nM) (Figure 10-4).  To determine 
whether the observed inhibition by candesartan cilexetil was due to the prodrug or degradation 
to candesartan, the stability of the prodrug in the three in vitro enzyme systems was assessed.  
Minimal degradation of candesartan cilexetil was observed in incubations with CYP26A1, 
CYP26B1 or CYP2C8 with only CYP2C8 showing any appreciable formation of the ester-
hydrolyzed product (Figure 10-5).  While all of the inhibitors tested exhibited some degree of 
inhibition of both CYP26A1 and CYP26B1, benzbromarone (12.0-fold), fluconazole (28.3-fold), 
quercetin (39.9-fold) and zafirlukast (11.8-fold) were all identified as relatively selective inhibitors 
for CYP26A1 while repaglinide (12.6-fold) showed selectivity towards inhibition of CYP26B1.  
IC50 values obtained with the set of 17 compounds for CYP26A1 and CYP26B1 were then 
compared to previously reported CYP2C8 IC50 values (Table 10-1). A positive and statistically 
significant correlation was observed for CYP26A1 and CYP2C8 IC50 values (r
2 = 0.849; Figure 
10-6A).  Only a weak correlation (r2 = 0.258) was observed between the IC50 values obtained for 
CYP26B1 and CYP2C8 (Figure 10-6B).   
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Figure 10-3.  Single concentration (10 µM) inhibition screen using tazarotenic acid as a 
probe substrate of CYP26 activity. 
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Table 10-3.  IC50 values for tazarotenic acid sulfoxide formation in recombinant CYP26 
enzyme preparations by inhibitors of CYP2C8.  Values in parenthesis represent the 95% 
confidence intervals for the nonlinear regression analysis. 
 IC50 (µM) 
 
Inhibitor CYP26A1 CYP26B1 26B1 IC50 / 26A1 IC50 
Benzbromarone 
0.63 
(0.56-0.71) 
7.57 
(3.62-15.9) 
12 
Candesartan 
25.6 
(8.21-72.3) 
58.3 
(24.2-473) 
2.3 
Candesartan Cilexetil 
0.41 
(0.17-0.96) 
0.27 
(0.20-0.36) 
0.7 
Clotrimazole 
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(0.49-0.73) 
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0.93 
(0.62-1.26) 
8.48 
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9.1 
Quercetin 
1.92 
(1.49-2.46) 
76.2 
(9.26-628) 
40 
Raloxifene 
1.78 
(1.06-2.97) 
3.28 
(2.15-5.01) 
1.8 
Repaglinide 
7.73 
(5.14-11.6) 
0.61 
(0.36-1.01) 
0.1 
Ritonavir 
3.84 
(1.69-8.70) 
2.56 
(0.93-7.09) 
0.7 
Rosiglitazone 
11.9 
(4.77-30.1) 
8.47 
(3.57-20.1) 
0.7 
Tamoxifen 
21.4 
(7.85-58.3) 
14.0 
(5.84-33.4) 
0.7 
Zafirlukast 
0.06 
(0.04-0.08) 
0.71 
(0.48-1.05) 
12 
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Figure 10-4.  In vitro IC50 curves for select CYP26A1 or CYP26B1 inhibitors using 
tazarotenic acid as a probe substrate. 
Data points represent the average of incubations conducted in triplicate and IC50 values were 
calculated using a three-parameter inhibition model with the Hill slope fixed to 1.    
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Figure 10-5.  Stability of candesartan cilexetil in recombinant CYP26A1, CYP26B1 and 
CYP2C8 enzymes. 
No degradation of candesartan cilexetil was observed under conditions similar to those used in 
the IC50 assays with only CYP2C8 showing any appreciable formation of candesartan. 
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Figure 10-6.  Correlation Between IC50 Values for CYP2C8 and CYP26A1 or CYP26B1. 
Correlation between previously reported CYP2C8 IC50 values and CYP26A1 (r
2 = 0.849) or 
CYP26B1 (r2 = 0.258) IC50 values generated using tazarotenic acid as a probe substrate.  Lines 
represent unity (solid black), 3-fold difference (dotted red) and 10-fold difference (dotted black).   
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10.3.3. Computational Docking Simulations.   
Previous reports have implicated CYP2C8 in the metabolism of at-RA, the primary substrate of 
CYP26A1 and CYP26B1 (Nadin and Murray, 1999; Marill et al., 2000; McSorley and Daly, 
2000).  In order to compare the structural similarities between the active sites of CYP2C8 and 
either CYP26A1 or CYP26B1, homology models of the CYP26 isozymes were superimposed on 
the crystal structure of CYP2C8 (pdb 1PQ2).  Comparison of the CYP26A1 homology model to 
CYP2C8 resulted in an RMSD value of 3.013 between the two protein structures.  The RMSD 
value for the CYP26B1 protein structure and CYP2C8 was 4.624.  Visual examination of the 
active sites of the three cytochrome P450 isozymes revealed carboxylic acid binding residues 
located in comparable regions of the active site of CYP2C8 (Gly98, Asn99, Ser100), CYP26A1 
(Arg 86, Arg90) and CYP26B1 (Tyr372, Arg373) that have been suggested to interact with the 
carboxylic acid moiety of 9-cis-retinoic acid, at-RA, or tazarotenic acid (Gomaa et al., 2006; 
Karlsson et al., 2008; Schoch et al., 2008; Foti et al., 2016).   
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Figure 10-7.  Computational Docking of Clotrimazole, Zafirlukast and Candesartan 
Cilexitil into CYP26 Homology Models. 
Computational docking of clotrimazole (A, CYP26A1; B, CYP26B1), zafirlukast (C, CYP26A1) 
and candesartan cilexetil (D, CYP26B1) into the active sites of CYP26.  The docking orientation 
of clotrimazole in the active sites of CYP26A1 and CYP26B1 suggests the potential for the 
imidazole moiety to inhibit the enzyme through type II binding interactions.  Active site residues 
involved in the binding of zafirlukast in the active site of CYP26A1 (R90, W112, F222, and 
F299) and candesartan cilexetil in the active site of CYP26B1 (W117, F295, F299 and Y372) 
are similar to the active site residues known to be involved in retinoic acid binding for each 
isoform. 
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In order to rationalize the ligand binding of the known CYP2C8 inhibitors in the active 
sites of either CYP26A1 or CYP26B1, a number of computational docking experiments were 
performed.  Docking simulations were carried out for the most potent azole-containing 
compound (clotrimazole for both CYP26A1 and CYP26B1) as well as zafirlukast for CYP26A1 
and candesartan cilexetil for CYP26B1, two compounds hypothesized to not inhibit the enzymes 
through azole-heme interactions.  As shown in Figures 10-7a and 10-7b, docking clotrimazole in 
the active sites of the CYP26A1 and CYP26B1 homology model predicted the sp2 nitrogen of 
the imidazole ring to be oriented toward the iron of the heme prosthetic group at a distance of 
3.104 Å for CYP26A1 and 2.655 Å for CYP26B1.  Docking scores were similar for both 
CYP26A1 (-8.602) and CYP26B1 (-7.148).  When zafirlukast was docked in the active site of 
CYP26A1 (docking score = -11.688), the cyclopentyl moiety was predicted to be oriented 
towards the heme iron at an approximate distance of 3.316 Å (Figure 10-7c).  Key active site 
interactions included π-stacking between the methylindole ring and F222 and F299, as well as 
between the tolyl ring and P371.  Hydrogen bonding was predicted to occur between the 
sulfonyl oxygens of zafirlukast and R90.  For CYP26B1 and candesartan cilexetil, a favorable 
docking score of -11.200 was achieved with the benzene ring of the benzimidazole moiety 
located approximately 3.424 Å from the heme iron (Figure 10-7d).  The amino acid residues 
predicted to be involved in orienting candesartan cilexetil in the active site of CYP26B1 included 
Y372 (π-stacking interaction with the phenyl ring adjacent to the tetrazole moiety) as well as  
W117, I368 and G371.  
 
10.3.4. Spectral Binding Studies.   
To further evaluate the results of the computational docking simulations with clotrimazole, 
zafirlukast and candesartan cilexetil, spectral binding studies were performed.  Clotrimazole 
exhibited type II binding characteristics when incubated with CYP26A1, CYP26B1 and CYP2C8 
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as indicated by the observed maxima and minima of the UV-difference spectra (Figure 10-8).  
Spectral binding constants (Ks) were determined by nonlinear regression and were 533 nM, 
4945 nM and 1574 nM for CYP26A1, CYP26B1 and CYP2C8, respectively (Table 10-4).  No 
binding spectra could be obtained for zafirlukast or candesartan cilexetil in any of the systems 
tested (data not shown).   
As the clotrimazole spectral binding constants for CYP26A1 and CYP26B1 were 
approximately 21.6-fold and 98.9-fold higher than their respective IC50 values, the protein 
binding of clotrimazole under the relevant in vitro conditions was explored.  Under the conditions 
used in the in vitro CYP26A1, CYP26B1 and CYP2C8 IC50 assays, clotrimazole had fu values of 
0.661, 0.430 and 0.155, respectively.  In the spectral binding assay, clotrimazole fu values were 
0.025, 0.005 and 0.048 for CYP26A1, CYP26B1 and CYP2C8, respectively.  When corrected 
for protein binding, the IC50,u and Ks,u values for clotrimazole were within two-fold of each other 
for each isozyme, suggesting that coordination of the imidazole nitrogen of clotrimazole to the 
heme iron is the most likely mechanism of clotrimazole inhibition for these three enzymes.   
Table 10-4.  Spectral binding properties for clotrimazole in recombinant CYP26A1, 
CYP26B1 and CYP2C8. Values in parenthesis represent the 95% confidence intervals for 
the nonlinear regression analysis.  Standard error values are reported for fu and Ks data. 
 CYP26A1 CYP26B1 CYP2C8 
IC50 (nM) 
24.7 
(16.7-36.6) 
50.1 
(33.5-76.4) 
725 
(422-1120) 
fu (IC50 assay) 0.661 ± 0.042 0.430 ± 0.031 0.155 ± 0.024 
IC50,unb (nM) 16.3 21.5 112 
Ks (nM) 533 ± 71.8 4954 ± 640 1574 ± 569 
fu (spectral binding 
assay) 
0.025 ± 0.001 0.005 ± 0.0006 0.048 ± 0.002 
Ks,unb (nM) 13.3 24.7 75.5 
Binding Mechanism Type II Type II Type II 
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Figure 10-8.  Spectral binding results for clotrimazole with recombinantly expressed 
CYP26A1, CYP26B1 or CYP2C8. 
Data suggests enzyme inhibition occurs through type II binding interactions with the heme. Ks,unb 
affinity constants for CYP26A1 (13.3 nM), CYP26B1 (24.7 nM) and CYP2C8 (75.5 nM) were 
determined through nonlinear regression analysis (inset Figures) and corrected for nonspecific 
binding in the in vitro assays. 
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10.3.5. Calculation of Cmax,u / IC50.   
To characterize the potential clinical ramifications of the observed in vitro inhibition of CYP26A1 
and CYP26B1 by known inhibitors of CYP2C8, reported clinical plasma Cmax values following 
typical oral or topical doses were obtained from the literature.  Cmax values were corrected for 
plasma protein binding and compared to the in vitro IC50 values to obtain a Cmax,u / IC50 ratio for 
CYP26A1 and CYP26B1 (Table 10-5).  While total plasma concentrations following oral or 
topical administration for a number of the inhibitors exceeded their in vitro IC50 values, only 
clotrimazole and fluconazole exhibited maximum unbound concentrations which would suggest 
the potential for a meaningful interaction in vivo.  Following topical administration, total skin 
concentrations of clotrimazole were reported to be 67.3 µM.  Using plasma protein binding as a 
surrogate for the unbound fraction in the skin, Cmax,u / IC50 values for clotrimazole were 337 for 
CYP26A1 and 135 for CYP26B1.  The predicted Cmax,u / IC50 values following 200 mg BID oral 
administration of fluconazole were 44.0 and 1.56 for CYP26A1 and CYP26B1, respectively.   
10.4. Discussion. 
 Retinoic acid is a highly regulated signaling molecule that is involved in a host of 
dermatological, immunological and neurological functions through binding to the retinoic acid 
receptors and retinoid X receptors (Asselineau et al., 1989; Duester, 2008; Niederreither and 
Dolle, 2008; Raverdeau et al., 2012; Ransom et al., 2014; Raverdeau and Mills, 2014; 
Cunningham and Duester, 2015).  As such, the metabolic pathways that are involved in the 
regulation of retinoic acid represent potential targets that can be exploited to alter 
concentrations of retinoic acid in vivo.  Synthesis of retinoic acid begins with conversion of 
vitamin A (retinol) to retinal by alcohol dehydrogenases and short-chain dehydrogenases 
followed by the conversion of retinal to retinoic acid by retinaldehyde dehydrogenases (Roos et 
al., 1998; Chen et al., 2000b; Zhang et al., 2000; Marill et al., 2002).    Degradation of retinoic  
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Table 10-5.  Cmax,u / IC50 values for inhibitors of tazarotenic acid sulfoxidation. 
Cmax and fu data compiled from literature references as noted in the Materials and Methods.     
 
     
     Cmax,u/IC50 
Inhibitor Oral Dose 
Cmax 
(nM) 
fu,plasma 
Cmax, u 
(nM) 
CYP 
26A1 
CYP 
26B1 
Benzbromarone 100 mg 9236 0.010 92.4 0.147 0.012 
Candesartan 16 mg QD 270 0.002 0.38 < 0.001 < 0.001 
Clotrimazole 1% Topical 67300* 0.100 6730 337 135 
17α-Ethynylestradiol 30 µg 0.5 0.002 0.00085 < 0.001 < 0.001 
Fluconazole 200 mg BID 34606 0.890 30794 44.0 1.56 
Itraconazole 200 mg QD 919 0.002 1.80 0.003 0.011 
Mometasone 50 µg Inhaled 0.05 0.010 0.0005 < 0.001 < 0.001 
Montelukast 10 mg 925 0.010 8.90 0.077 0.015 
Pioglitazone 45 mg 4489 0.010 38.0 0.048 0.005 
Quercetin 500 mg TID 50.9 0.009 0.45 < 0.001 < 0.001 
Raloxifene 1 mg/kg 1.05 0.050 0.50 < 0.001 < 0.001 
Repaglinide 4 mg 104 0.026 2.60 < 0.001 0.004 
Ritonavir 600 mg BID 15258 0.010 150 0.040 0.060 
Rosiglitazone 8 mg 1673 0.002 3.40 < 0.001 < 0.001 
Tamoxifen 10 mg BID 323 0.020 6.40 < 0.001 < 0.001 
Zafirlukast 20 mg BID 1125 0.010 3.00 0.188 0.016 
 
* Represents reported clotrimizole concentration in skin (stratum corneum) following topical 
administration of a 1% clotrimazole cream formulation. 
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acid occurs through oxidation to 4-hydroxy-, 16-hydroxy-, and 18-hydroxyretinoic acid, which is 
catalyzed primarily by the CYP26-family (CYP26A1, CYP26B1 and CYP26C1) as well as by 
CYP2C8, CYP2C9 and CYP3A (Leo et al., 1989; Sonneveld et al., 1998; Nadin and Murray, 
1999; Chen et al., 2000a; Marill et al., 2000; McSorley and Daly, 2000; Marill et al., 2002; Taimi 
et al., 2004; Lutz et al., 2009; Thatcher and Isoherranen, 2009; Thatcher et al., 2010; Helvig et 
al., 2011; Topletz et al., 2012).  As such, the ability to modulate these pathways may prove to 
have a significant therapeutic benefit.   
CYP2C8 was one of the first enzymes identified in the formation of 4-hydroxyretinoic 
acid and is the only drug metabolizing enzyme for which a crystal structure with a retinoic acid 
isomer bound in the active site exists (Leo et al., 1989; Nadin and Murray, 1999; Schoch et al., 
2008).  The enzyme is the major hepatic isoform involved in 13-cis-retinoic acid metabolism and 
can be inhibited by retinol and retinoic acid (Yamazaki and Shimada, 1999; McSorley and Daly, 
2000; Marill et al., 2002).  Given the propensity for CYP26A1, CYP26B1 and CYP2C8 to both 
metabolize and to be inhibited by the same retinoids, the potential exists for the inhibitory 
pharmacophores of CYP2C8 and CYP26 to overlap.  Indeed, when homology models of 
CYP26A1 and CYP26B1 built using CYP120 (pdb 2VE3) as a template were superimposed on 
the CYP2C8 crystal structure (pdb 1PQ2), RMSD values of 3.013 and 4.624 were calculated, 
respectively.  Furthermore, closer inspection of the active sites of CYP26A1, CYP26B1 and 
CYP2C8 suggest the presence of carboxylic acid binding residues in similar spatial proximity to 
the heme prosthetic group.  Previous work to solve the crystal structure of CYP2C8 with 9-cis-
retinoic acid bound in the active site suggests Gly98, Asn99 and Ser100 are important residues 
in anchoring the carboxylate moiety of the retinoic acid molecule which undergoes catalysis 
(CYP2C8 simultaneously binds two molecules of 9-cis retinoic acid) while CYP26A1 or 
CYP26B1 homology models built off of various templates have indicated that the carboxylate of 
retinoic acid forms hydrogen bonds with Arg64 (Shimshoni et al., 2012), Arg86 (Gomaa et al., 
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2006) or Arg90 (Karlsson et al., 2008; Foti et al., 2016) for CYP26A1 and Arg95 and Ser369 
(Karlsson et al., 2008; Saenz-Mendez et al., 2012) or Tyr372 and Arg373 (Foti et al., 2016) for 
CYP26B1.  The estimated active site volumes of CYP26A1 (918 Å3) and CYP26B1 (977 Å3) 
based on homology modeling are somewhat smaller than the volume of the active site 
measured from the crystal structure of CYP2C8 (1438 Å3), though it would appear they are large 
enough to accommodate larger xenobiotic compounds, similar to other CYP isoforms (Schoch 
et al., 2004; Foti et al., 2016). 
In order to test the hypothesis of whether CYP26A1 and CYP26B1 were capable of 
binding xenobiotics with a similar pharmacophore profile as CYP2C8, a set of known CYP2C8 
inhibitors was screened for inhibition activity against CYP26A1 and CYP26B1.  Recently, 
tazarotenic acid has been identified as a substrate of CYP26A1 and CYP26B1 (Foti et al., 
2016).  To verify the use of tazarotenic acid sulfoxide formation as a probe for CYP26 activity, 
inhibition data was generated for known CYP26 inhibitors and compared to IC50 values 
previously obtained using 9-cis-retinoic acid.  The observed r2 values suggest that tazarotenic 
acid is an appropriate probe substrate to assess the inhibition of CYP26A1 and CYP26B1 in 
vitro (Figure 10-2), though the possibility of substrate-dependent inhibition profiles cannot be 
ruled out.  While the compounds rank-ordered in a similar fashion between the two assays, 
some notable differences were observed.  Calculated IC50 values for CYP26A1 using 
tazarotenic acid as a probe substrate were lower than those using 9-cis-retinoic acid.  
Interestingly, the reverse was generally true for CYP26B1, with 9-cis-retionic acid IC50 values 
being lower than those generated using tazarotenic acid.   
 The inhibition profile of CYP2C8 has received a great deal of attention owing to its role in 
clinically relevant drug interactions.  Inhibition of CYP2C8 is thought to be partially responsible 
for the observed drug interactions between fluvoxamine and rosiglitazone as well as between 
gemfibrozil and montelukast, rosiglitazone, pioglitazone, repaglidide, cerivastatin and 
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loperamide (Backman et al., 2002; Niemi et al., 2003; Deng et al., 2005; Jaakkola et al., 2005; 
Niemi et al., 2006; Tornio et al., 2008; Karonen et al., 2010; Honkalammi et al., 2011).  To 
further characterize the drug interaction profile of CYP2C8, a significant amount of in vitro 
efforts have been reported, with compounds such as montelukast, candesartan cilexetil, 
zafirlukast and clotrimazole having sub-micromolar IC50s (Walsky et al., 2005; VandenBrink et 
al., 2011).  In the current study, multiple CYP2C8 inhibitors were identified as potent inhibitors of 
both CYP26 isoforms.  Selective inhibitors of CYP26A1 (versus CYP26B1) included quercetin, 
fluconazole, benzbromarone, and zafirlukast while repaglinide was the only compound with a 
10-fold or greater selectivity for CYP26B1 inhibition.  The difference in inhibition profiles 
between the two enzymes suggests differences in the active site characteristics which lead to 
inhibitor binding as well as to the potential to identify novel chemical scaffolds with which to 
achieve selective inhibition of CYP26A1 or CYP26B1.  When the IC50 values were compared to 
previously reported CYP2C8 IC50 values, a statistically significant correlation was observed for 
CYP26A1 (r2 = 0.849), suggesting that compounds which are inhibitors of CYP2C8 may also be 
inhibitors of CYP26A1.  Perhaps further supporting the possibility for substrate-dependent 
inhibition profiles for CYP26 are the IC50 values observed for clotrimazole, fluconazole, quercetin 
and tamoxifen, four compounds previously reported to not be inhibitors of CYP26A1-catalyzed 
4-hydroxyretinoic acid formation from 9-cis-retinoic acid in vitro (Foti et al., 2011). 
 To further characterize the active site binding interactions that lead to inhibition of 
CYP26A1 and CYP26B1, the spectral binding characteristics of the most potent azole-
containing compound for each enzyme, clotrimazole, were evaluated.  In addition, the binding of 
the most potent inhibitor of CYP26A1 (zafirlukast) and CYP26B1 (candesartan cilexetil) which 
was hypothesized to not inhibit each enzyme through heme-azole interactions was 
characterized.  Computational simulations with homology models of CYP26A1 or CYP26B1 
predicted that clotrimazole would bind in the active site of each enzyme with the sp2 nitrogen of 
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the imidazole ring oriented toward the heme (Figure 10-7a and 10-7b).  Zafirlukast, which does 
not contain any structural moieties amenable to heme coordination, docked with its cyclopentyl 
moiety oriented towards the heme (Figure 10-7c).   Interestingly, CYP26B1 docking of 
candesartan cilexetil, which contains a tetrazole moiety theoretically capable of coordinating to 
the heme iron, suggested that interactions with active site residues, rather than heme-azole 
coordination, were responsible for orienting candesartan cilexetil in the active site of CYP26B1 
with the tetrazole moiety oriented in a distal fashion from the heme (Figure 10-7d).  Indeed, 
when spectral studies were conducted, only clotrimazole exhibited a type II binding spectra for 
both CYP26A1 and CYP26B1, indicating that the imidazole nitrogen of clotrimazole was 
coordinated to the heme.  Other known type II inhibitors of CYP26 activity in vitro include 
ketoconazole, R115866 and R116010 (Thatcher et al., 2011). 
 The comparison of unbound inhibitor concentrations in vivo, [I], to in vitro IC50 or Ki 
values is a commonly used method to predict clinically relevant drug interactions.  For reversible 
inhibitors, [I]/Ki values of between 0.1 and 1 suggest the possibility of a clinically relevant drug 
interaction while an [I]/Ki greater than 1 implies the interaction is likely (Bjornsson et al., 2003a; 
Bjornsson et al., 2003b; Kosugi et al., 2012).  Using IC50 values as a surrogate for Ki, the ratio of 
unbound Cmax values for clotrimazole and fluconazole to their respective inhibition potencies 
suggest the potential for these two compounds to inhibit CYP26 activity either locally 
(clotrimazole) or systemically (fluconazole).  The low bioavailability of clotrimazole implies that 
even with high skin concentrations of the drug, systemic effects are unlikely (Sawyer et al., 
1975).  The effect of antifungal drugs such as clotrimazole and fluconazole on retinoic acid 
concentrations has been previously reported, though the overall role of CYP26 in these 
interactions remains to be determined.  For example, the Cmax and AUC of orally administered 
retinoic acid were shown to increase 6-fold and 4-fold, respectively, in a patient with acute 
promyelocytic leukemia upon co-administration of oral fluconazole (Schwartz et al., 1995).  A 
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second case study on a patient with the same form of leukemia receiving oral retinoic acid 
described the onset of pseudotumor cerebri, a CNS toxicity, upon administration of oral 
fluconazole, a condition which resolved after discontinuation of the fluconazole treatment 
(Vanier et al., 2003).  While inhibition of CYP2C8, CYP2C9 and CYP3A4 by fluconazole may 
also be involved in the reported drug interactions, the contribution of CYP26A1 or CYP26B1 
cannot be ruled out, and may provide an plausible mechanism for the teratogenicity often 
associated with fluconazole in humans and animal models (Tiboni, 1993; Menegola et al., 2001; 
Lopez-Rangel and Van Allen, 2005; Tiboni and Giampietro, 2005).  In addition to clinical drug 
interactions, additional evidence exists in vitro and in pre-clinical species in regard to the effects 
of antifungal drugs on retinoic acid metabolism.  For example, the combination of clotrimazole 
and at-RA has been shown to initiate cellular differentiation in retinoic acid-resistant cell lines 
and to inhibit retinoic acid metabolism in embryonic carcinoma cells, while a modest induction of 
murine CYP26 embryonic mRNA expression is observed after administration of teratogenic 
doses of fluconazole, perhaps in response to an increase in at-RA concentration (Williams and 
Napoli, 1987; Kizaki et al., 1996; Tiboni et al., 2009).  Similar to the clinical drug interactions 
observed between retinoic acid and fluconazole, while not definitive, the role of CYP26 in these 
in vitro interactions warrants further consideration.   
In conclusion, the results demonstrate that CYP26A1 and CYP26B1 are inhibited by 
many known inhibitors of CYP2C8.  The overlap in inhibitory pharmacophores between 
CYP2C8 and CYP26A1 or CYP26B1 may be driven by similarities in the active site binding 
characteristics of each enzyme and may open the possibility to expand upon the known 
pharmacophores related to inhibition of retinoic acid metabolism.  Further, the potential for 
inhibition of CYP26 to cause clinically relevant drug interactions suggests care should be taken 
when co-administering retinoic acid and potent inhibitors such as fluconazole or clotrimazole.  
Ultimately, the results expand upon the contributions of CYP26A1 and CYP26B1 to drug 
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metabolism and drug interactions and should serve to increase the understanding of the 
enzymes as both a drug target and in regard to patient safety.   
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11. Chapter IV:  Contribution of CYP26 to the Metabolism and Clearance of Retinoic 
Acid Receptor Agonists and Antagonists 
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11.1. Introduction. 
 The cytochrome P450 family of drug metabolizing enzymes is responsible for the 
oxidative metabolism of many endogenous compounds and most xenobiotics (Nelson, 2006; 
Zanger and Schwab, 2013).  Within the cytochrome P450 family, CYP26A1, CYP26B1 and 
CYP26C1 are involved to varying extents in the regulation of endogenous retinoic acid 
concentrations (Ray et al., 1997; Taimi et al., 2004; Guengerich, 2006; Lutz et al., 2009; 
Thatcher and Isoherranen, 2009; Ross and Zolfaghari, 2011).  While CYP26A1 and CYP26B1 
are expressed in multiple tissues throughout the adult human body, expression of CYP26C1 is 
believed to be relatively limited (Xi and Yang, 2008; Thatcher and Isoherranen, 2009; Thatcher 
et al., 2010; Topletz et al., 2012; Brown et al., 2014).  On the basis of mRNA expression, 
primary sites of CYP26A1 expression include the testes, lung, kidney and skin, with CYP26B1 
also being expressed in the testes, lung and skin, as well as the intestine, placenta and ovaries 
(Xi and Yang, 2008; Osanai and Lee, 2011; Topletz et al., 2012).  The known catalytic activities 
of CYP26A1 and CYP26B1 highly overlap, with substrates including retinoic acid isomers, 
metabolites of retinoic acid and at least one known xenobiotic compound, tazarotenic acid 
(White et al., 1996; Sonneveld et al., 1998; White et al., 2000; Taimi et al., 2004; Lutz et al., 
2009; Thatcher et al., 2010; Ross and Zolfaghari, 2011; Shimshoni et al., 2012; Topletz et al., 
2012; Topletz et al., 2014; Foti et al., 2016).   
In order to maintain cellular homeostasis, the regulation of endogenous retinoic acid 
concentrations is a highly ordered process with alterations often resulting in the onset of 
pharmacological and toxicological effects (Lotan, 1980; Sporn and Roberts, 1984; McCaffery 
and Drager, 2000; Ross et al., 2000; Clagett-Dame and DeLuca, 2002; Maden, 2002).  The 
mechanism of action for the observed effects in humans involves the binding of retinoic acid to 
retinoic acid receptors (,  and ) as well as retinoid X receptors (,  and ) with the 
subsequent downstream effects including changes in gene expression which ultimately can 
impact cellular proliferation and differentiation (Levin et al., 1992; Mangelsdorf et al., 1992; Mark 
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et al., 2006; Altucci et al., 2007; di Masi et al., 2015).  As such, the development of retinoic acid 
receptor agonists and antagonists represents an area of scientific interest throughout a number 
of therapeutic areas and disease states (Pawson et al., 1982). 
Multiple of retinoic acid receptor agonists and antagonists, often structurally related to 
retinoic acid, are either in use clinically or in development for various indications, including 
dermatological disorders and multiple forms of cancer (Charpentier et al., 1995; di Masi et al., 
2015).  While it is quite common to assess the selectivity of such compound across the panel of 
retinoic acid- or retinoid X receptors, often much less is known about the adsorption, 
distribution, metabolism and excretion (ADME) properties of these compounds, and in 
particular, very little information currently exists with regard to the drug metabolizing enzymes 
responsible for their biotransformation.  Recently, tazarotenic acid, the active metabolite of 
tazarotene (a retinoic acid receptor / agonist), was shown to be a substrate for CYP26A1 and 
CYP26B1 in vitro (Foti et al., 2016).  As such, the possibility exists for other RAR agonists and 
antagonists to be substrates for the CYP26 family of drug metabolizing enzymes.   
  The primary aim of this work was to characterize the ability of the CYP26s (CYP26A1, 
CYP26B1 and CYP26C1) to metabolize various retinoic acid receptor agonists and antagonists 
in vitro.  In vitro clearance assays were used as an initial screen to determine the clearance 
parameters for thirteen compounds.  Based on the rates of metabolite formation by all three 
CYP26 isozymes, adapalene was selected for further evaluation, including a full phenotyping 
assessment as well as more in-depth metabolite identification studies.  Finally, computational 
docking experiments were used to rationalize the ligand interactions leading to the observed 
metabolic profile of adapalene and des-adamantyl adapalene for each of the CYP26 isozymes.  
The results presented herein further support the role of the CYP26 family of drug metabolizing 
enzymes in the metabolism of xenobiotic compounds, especially those structurally related to 
retinoic acid.   
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11.2. Materials and Methods. 
11.2.1. Materials.   
Retinoic acid receptor agonists, antagonists and metabolites were obtained from Tocris 
Chemicals (Bristol, United Kingdom).  Des-adamantyl adapalene was a generous gift from Dr. 
Philippe Diaz (University of Montana).  Recombinant CYP26A1, CYP26B1 and CYP26C1 were 
generous gifts from Dr. Nina Isoherranen (University of Washington).  All other in vitro enzymes 
were purchased from Corning (Tewksbury, MA).  The remainder of the reagents and solvents 
were purchased from Sigma-Aldrich (St. Louis, MO) and were of the highest grade available.   
 
11.2.2. In Vitro Clearance of Retinoic Acid Receptor Agonists and Antagonists by 
Recombinant CYP26s, CYP2C8 and CYP3A4.   
Incubations to determine the intrinsic clearance of a set of RAR ligands (Figure 11-1) in 
recombinant CYP2C8, CYP3A4, CYP26A1 and CYP26B1 consisted of 5 nM of the relevant 
cytochrome P450 enzyme, 25 nM purified human reductase, 200 nM substrate and 1 mM 
NADPH in 100 mM potassium phosphate buffer (pH 7.4; final volume = 750 µL).  An initial 
screen using a single end point (20 minutes) was initially conducted to assess turnover in each 
in vitro system.  For compounds exhibiting more than 20% turnover by any single enzyme, in 
vitro clearance experiments were repeated with aliquots being removed at 0, 1, 2.5, 5, 15, 30, 
45 and 60 minutes and immediately quenched with 3 volumes of ice-cold acetonitrile containing 
tolbutamide as an internal standard and centrifuged as noted above prior to analysis by LC-
MS/MS.  Control incubations were carried out in the absence of NADPH.   
 
 
 
 
105 
 
 
 
Figure 11-1.  Retinoic acid receptor agonists and antagonists included in intrinsic 
clearance experiments in recombinant CYP26A1, CYP26B1, CYP26C1, CYP2C8 and 
CYP3A4. 
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11.2.3. Adapalene Phenotyping.   
Incubations performed to determine the enzymes responsible for the metabolism of adapalene 
contained recombinant enzyme (5 nM, final concentration), purified human reducatase (50 nM, 
final concentration) and adapalene (500 nM, final concentration) in potassium phosphate buffer 
(100 mM, pH 7.4).  After a pre-incubation period of three minutes at 37 ºC, NADPH (1 mM, final 
concentration) was added to all incubations.  Incubations which contained flavin-containing 
monooxygenase (FMO) enzymes were pre-incubated with enzyme and NAPDH and initiated by 
addition of adapalene because of the lack of stability of FMOs at 37 ºC (Foti and Fisher, 2004).  
All incubations (50 µL, final volume) were kept at 37 ºC for 20 minutes before being stopped 
through addition of 3 volumes (v/v) of ice-cold acetonitrile.  Tolbutamide (500 nM, final 
concentraition) was utilized as the internal standard.  Samples were mixed and subject to 
centrifugation (3000 RPM) for fifteen minutes before analysis by LC-MS/MS.   
 
11.2.4. Metabolite Identification of Adapalene and Des-Adamantyl Adapalene in 
Recombinant CYP26s.  
 
In vitro experiments to elucidate the metabolic pathways of adapalene in CYP26A1, CYP26B1 
or CYP26C1 recombinant preparations were carried out using 50 nM recombinant enzyme, 200 
nM purified human reducatase and adapalene (10 µM) in 100 mM potassium phosphate buffer 
(pH 7.4).  Incubations were initiated with the addition of 1 mM NADPH (final concentration) and 
incubated at 37 ºC for 30 minutes.  Control incubations were performed in the absence of 
NADPH.  Upon completion, in vitro incubations were extracted into 4 volumes of ethyl acetate, 
dried under a gentle stream of N2 at 40 ºC and reconstituted in 100 µl methanol prior to LC-
MS/MS analysis and compared to commercially available synthetic standards of each 
metabolite.   
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11.2.5. Computational Docking of Adapalene and Des-Adamantyl Adapalene in CYP26A1, 
CYP26B1 and CYP26C1 homology models.   
 
Three dimensional homology models of CYP26A1 and CYP26B1 were designed and validated 
as described in previous chapters.  Subsequently, a three dimensional homology model of 
CYP26C1 was also designed using Prime (Schrodinger LLC, New York).  The CYP26C1 amino 
acid sequence was obtained from the NCBI protein server (UniProtKB/Swiss-Prot Accession 
Number: Q6V0L0.2; Gene ID 340665).  As with the CYP26A1 and CYP26B1 homology models, 
the crystal structure of CYP120 (pdb 2VE3) was also used as the template for the CYP26C1 
homology model.  Sequence similarity between CYP26C1 and CYP120 was indicated by a 35% 
sequence identity and 52% positive sequence coverage (Table 11-1).  A heme prosthetic group 
was introduced into the homology model and covalently bound to Cys459 upon which an energy 
minimization step using OPLS_2005 force field constraints (contained within the MacroModel 
algorithm (Schrodinger LLC, New York)) was conducted.  For docking of adapalene or des-
adamantyl adapalene in the active site of the CYP26C1 homology model, the available docking 
space was defined by a 12 x 12 x 12 Å cube to constrain the center of mass of the ligands using 
Glide (Schrodinger LLC, New York).  The structural plausibility of the CYP26C1 homology 
model was evaluated through Ramachandran plots, calculation of unacceptable bond lengths 
and angles and scoring of model flexibility using PSIPRED (University College London, UK) and 
SSPro (Schrodinger).  Adapalene and des-adamantyl adapalene three dimensional structures 
were energy minimized using the OPLS_2005 force field constraints as defined within the 
LigPrep algorithms (Schrodinger LLC, New York).  Multiple scoring algorithms were used to 
assess the docking poses of the ligands within the active site of each enzyme (Perola et al., 
2004). 
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Table 11-1.  Estimated parameters for the CYP26C1 homology model. 
Parameter CYP26C1 Model 
Template CYP120 (pdb 2VE3) 
Template Sequence Identity 35% 
Template Positive Sequence Coverage 52% 
BLAST Query Coverage 89% 
BLAST E-Value 3e-83 
RMSD vs Template 0.789 
Favorable Bond Angles 84.7% 
Allowable and Favorable Bond Angles 94.9% 
I-Helix Residues M283 – L312 
Active Site Volume (A3) 1090.1 
  
 
 
Figure 11-2. CYP26C1 Ramachandran Plot. 
Analysis of the Phi-Psi angles in the CYP26C1 homology model demonstrated 94.9% of the 
angles were in the favorable or allowable regions. 
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11.2.6. LC-MS/MS Analysis.   
Analysis of the retinoic acid receptors and their metabolites was conducted using LC-MS/MS 
methods.  The analytical instrumentation was identical to that described in previous chapters.  In 
brief, an Applied Biosystems API4000 utilizing an electrospray ionization source (Applied 
Biosystems, Foster City, CA) was coupled to a liquid chromatography / sample introduction 
system that was comprised of LC-20AD binary pumps and an in-line solvent degasser 
(Shimadzu, Columbia, MD).  The injection volume used for all analytical samples was 10 μL.  
For intrinsic clearance experiments, peak separation was accomplished using 0.1% formic acid 
(v/v) in water (mobile phase A) or acetonitrile (mobile phase B) and a Synergi 2.5 µm Hydro RP 
100 Å (50 x 2.0 mm) analytical column (Phenomenex, Torrance, CA).  A rapid gradient similar to 
that described in previous chapters was used.  For adapalene and des-adamantyl adapalene 
metabolite elucidation experiments, a Kinetex 2.6 µm C18 100 Å (100 x 2.1 mm) column 
(Phenomenex, Torrance, CA) was used to achieve peak separation.  A longer gradient was 
used for metabolite elucidation samples, beginning with 2.5% B (0 – 3 minutes), increasing from 
2.5% B to 95% B (from 3 – 14 minutes), holding at 95% B (from 14 – 17 minutes) and re-
equilibrating at 2.5% B for 3 minutes prior to the injection of the next sample.  LC-MS/MS 
analyses for intrinsic clearance experiments utilized multiple reaction monitoring (MRM).  A 
rapid screen for the formation of oxidative metabolites (+16 amu) was performed by increasing 
the Q1 mass value by 16 amu and by both increasing the Q3 mass value by 16 amu as well as 
by holding it constant for each metabolite.  Additional metabolite identification analyses for 
adapalene and des-adamantyl adapalene also utilized full Q1 scans (100 – 1000 amu).  Generic 
parameters that were utilized for all analytes included the curtain gas (14 arbitrary units), CAD 
gas (medium), ion spray voltage (4500 V), source temperature (550 °C) and ion source gas 1 
and gas 2 (35 arbitrary units, each). 
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11.2.7. Data Analysis.   
Analysis of raw data was was performed through Analyst (version 1.5; Applied Biosystems, 
Foster City, CA).  Concentrations of each analyte of interest were calculated by comparing the 
peak areas of an unknown sample to the peak area that was determined from standard curves 
with synthetic standards.  Parameter fitting for intrinsic clearance was accomplished with 
WinNonlin (Phoenix64, Cetara, Princeton, NJ) as described below.   
Intrinsic clearance values were calculated by first determining substrate depletion rates 
through the normalization of remaining analyte concentrations to a percent of initial 
concentration remaining (T0).  Linear regression was employed to calculated the slope (-k) of 
the ln(percent remaining) values as a function of time as previously described (Obach et al., 
1997).  An in vitro clearance value (mL/min/nmol cytochrome P450) was then determined by 
converting the resulting rate value (k) to an in vitro half-life (T1/2 = 0.693 / k) as shown in 
Equation 1. 
 
Equation 1   
ContentCYP
VolumeIncubation
T
Cl appInVitro 
2/1
,
693.0
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11.3. Results 
11.3.1. In Vitro Clearance of Retinoic Acid Receptor Agonists and Antagonists by 
Recombinant CYP26s, CYP2C8 and CYP3A4.   
An initial metabolic stability screen was conducted in order to determine the percent remaining 
for each of the 13 retinoic acid receptor ligands after a 20 minute incubation in recombinant 
CYP26A1, CYP26B1, CYP26C1, CYP2C8 or CYP3A4 (Table 11-2).  The retinoic acid receptor 
agonists with the highest degree of turnover were SR11237 (CYP26A1 and CYP3A4), 
tazarotenic acid (CYP26B1), and MM11253 (CYP26C1 and CYP2C8). 
 
 
Table 11-2.  Percent remaining of RAR ligands at 20 min in CYP 26A1, 26B1, 26C1, 2C8 
and 3A4. 
 Percent Parent Compound Remaining at 20 minutes 
Compound CYP26A1 CYP26B1 CYP26C1 CYP2C8 CYP3A4 
Adapalene 96 78 68 102 102 
AM80 104 88 93 99 94 
AM580 93 44 102 105 96 
Bexarotene 98 74 103 4 18 
BMS 753 82 106 104 107 83 
BMS 961 104 102 16 38 76 
CD437 108 95 97 2 106 
EC23 71 98 103 107 68 
MM11253 46 87 9 0 46 
SR11237 35 72 81 3 7 
Talarozole 98 86 88 96 68 
Tazarotenic Acid 51 42 52 86 104 
TTNPB 68 66 58 105 81 
 
 Intrinsic clearance values were determined for any retinoic acid receptor ligand which 
displayed greater than 20% depletion over the 20 minute incubation (Table 11-2).  Both 
adapalene (CYP26B1 and CYP26C1) and tazarotenic acid (CYP26A1, CYP26B1 and 
CYP26C1) were shown to be primarily cleared by the CYP26s with only minimal involvement by 
either CYP2C8 or CYP3A4.   The highest intrinsic clearance observed for any of the CYP26-
catalyzed reactions was with CYP26A1 and SR11237, which had an intrinsic clearance of 3.76 
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± 0.28 mL/min/nmol P450 (Table 11-3, Figure 11-3).  Conversely, the highest rates of 
metabolite formation were observed with AM580 (CYP26A1) and adapalene (CYP26B1 and 
CYP26C1) (Figure 11-4). 
 
 
 
Table 11-3.  Intrinsic clearance parameters for RAR ligands in recombinant CYP26A1, 
CYP26B1, CYP26C1, CYP2C8 and CYP3A4. 
Compound Enzyme Clint (mL/min/nmol P450) 
Adapalene CYP26B1 0.24 ± 0.01 
 CYP26C1 0.38 ± 0.03 
AM580 CYP26B1 0.84 ± 0.02 
Bexarotene CYP26B1 0.30 ± 0.04 
 CYP2C8 3.22 ± 0.12 
 CYP3A4 1.71 ± 0.18 
BMS961 CYP26C1 2.49 ± 0.21 
 CYP2C8 0.96 ± 0.16 
 CYP3A4 0.27 ± 0.08 
CD437 CYP2C8 3.91 ± 0.31 
EC23 CYP26A1 0.84 ± 0.05 
 CYP3A4 1.26 ± 0.24 
MM11253 CYP26A1 0.78 ± 0.16 
 CYP26C1 2.41 ± 0.41 
 CYP2C8 7.37 ± 0.69 
 CYP3A4 1.21 ± 0.09 
SR11237 CYP26A1 3.76 ± 0.28 
 CYP26B1 0.33 ± 0.08 
 CYP2C8 15.6 ± 2.61 
 CYP3A4 2.66 ± 0.24 
Talarazole CYP3A4 0.39 ± 0.09 
Tazarotenic Acid CYP26A1 0.67 ± 0.07 
 CYP26B1 1.08 ± 0.21 
 CYP26C1 0.65 ± 0.11 
TTNPB CYP26A1 1.05 ± 0.05 
 CYP26B1 0.42 ± 0.06 
 CYP26C1 0.54 ± 0.12 
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Figure 11-3.  Depletion rates of retinoic acid receptor agonists and antagonists in 
recombinant CYP26A1, CYP26B1 and CYP26C1. 
Substrates were incubated at 200 nM for 20 minutes at 37 °C.  SR11237, tazarotenic acid and 
MM11253 exhibited the highest degrees of depletion by CYP26A1, CYP26B1 and CYP26C1, 
respectively. 
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Figure 11-4.  Metabolite formation rates of retinoic acid receptor agonists and 
antagonists 1n recombinant CYP26A1, CYP26B1 and CYP26C1. 
Oxidative metabolism (+16 amu) was monitored over 20 minutes by LC-MS/MS.  AM580 
(CYP26A1) and adapalene (CYP26B1 and CYP26C1) exhibited the highest rates of metabolite 
formation over the 20 minute incubation period.  Dashed lines represent 100% of T0. 
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11.3.2. Metabolite Identification of Adapalene and Des-Adamantyl Adapalene in 
Recombinant CYP26s.   
Experiments were conducted to deduce the major sites of metabolism for adapalene and des-
adamantyl adapalene in recombinant CYP26 incubation.  In incubations with adapalene and 
CYP26A1, CYP26B1 and CYP26C1, the only metabolite observed was hydroxylation of the 
adamantane ring (Figure 11-5).  To assess the steric effects of the adamantyl moiety, a des-
adamantyl analog of adapalene was also profiled.  When des-adamantyl adapalene was used 
as the substrate with any of the CYP26 isozymes, the only metabolite observed was O-
demethylation of the methoxyphenyl moiety (Figure 11-6).  No additional sites of oxidative 
metabolism were observed for either adapalene or des-adamantyl adapalene.  
 
Figure 11-5. Metabolite elucidation of adapalene in recombinant CYP26C1. 
Incubating adapalene with recombinant CYP26C1 produced a single hydroxylated metabolite.  
Analysis of mass spectrometry fragmentation patterns suggests the adamantyl moiety is the site 
of hydroxylation.  Similar data was observed with recombinant CYP26A1 and CYP26B1 (data 
not shown). 
Adapalene-OH
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Figure 11-6.  Assessment of des-adamantyl adapalene metabolite formation in 
recombinant CYP26C1. 
Incubation of des-adamantyl adapalene with recombinant CYP26C1 produced a single 
metabolite at a molecular weight of 14 amu less that the parent molecule.  Analysis of mass 
spectrometry fragmentation patterns suggests the metabolite is O-desmethyl-desadamantyl 
adapalene.  Similar data was observed with recombinant CYP26A1 and CYP26B1 (data not 
shown). 
  
 
11.3.3. Computational Docking of Adapalene and Des-Adamantyl Adapalene in CYP26A1, 
CYP26B1 and CYP26C1 homology models.  
 To characterize the ligand-protein interactions of adapalene that lead to its observed metabolic 
profile by CYP26A1, CYP26B1 and CYP26C1, the compound was computationally docked into 
homology models of each enzyme.  The design and validation of the CYP26A1 and CYP26B1 
homology models are as previously described.  A BLAST search using the amino acid 
sequence of CYP26C1 (UniProtKB/Swiss-Prot Accession Number: Q6V0L0.2; Gene ID 340665) 
identified the crystal structure of CYP120 (pdb 2VE3) as being the closest match upon which to 
base the homology model, similar to what was observed for CYP26A1 and CYP26B1.  
6 8 1 0 1 2 1 4
0
1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
4 0 0 0 0
5 0 0 0 0
T im e  (m in u te s )
In
s
tr
u
m
e
n
t 
R
e
s
p
o
n
s
e
  
(c
p
s
)
NADPH
No NADPH
des-adamantyl-adapalene
O-desmethyl
metabolite
*
117 
 
Comparison of the protein sequences for CYP26C1 and CYP120 revealed a sequence identity 
of 35%, a positive sequence coverage of 52% and a BLAST query coverage of 89%.  An RMSD 
value of 0.789 was calculated by superimposing the CYP26C1 homology model on the crystal 
structure of CYP120.  A number of similarities to the CYP26A1 and CYP26B1 active sites were 
observed, namely aromatic, hydrophobic interactions with Phe222, Phe295 and W117 as well 
as amino acid residues able to interact with a carboxylate moiety distal from the heme iron 
(Trp65, His73 and Tyr387).  Additional amino acid residues involved in defining the active site of 
CYP26C1 included Glu292, Val383 and Ser384.  The I-helix was defined by residues Met283 
through Leu312.  Homology model parameters are shown in Table 11-1 and the resulting 
Ramachandran plot in Figure 11-2.  Estimation of the active site volume of CYP26C1 indicated 
a cavity of approximately 1090 Å3 (Figure 11-7) 
Prior to docking adapalene into the CYP26C1 homology model, the model was further 
evaluated by docking at-RA into the active site.  As expected, at-RA was positioned with the -
ionone moiety proximal to the heme prosthetic group with the carboxylate of at-RA distal to the 
heme and predicted to have a hydrogen bonding interaction with Trp65 (Figure 11-8). Other 
amino acid residues located within 4 Å of the at-RA molecule included Trp117, Phe222, 
Phe295, Val383 and Ser384.  In this orientation, the hydrogen atoms whose abstraction would 
facilitate formation of 16-hydroxy-at-RA were positioned approximately 3.37 Å from the heme 
iron.  The model was unable to resolve binding orientation conducive to 4- or 18 hydroxylation of 
at-RA, though it should be noted that the metabolic profile of at-RA in vitro has yet to be fully 
characterized. 
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Figure 11-7.  Characterization of the active site of the CYP26C1 homology model. 
The ligand binding site of CYP26C1 was defined primarily by lipophilic aromatic amino acid 
residues (W117, F222 and F295) and by ionizable hydrogen bonding residues capable of 
interacting with the carboxylate moiety of retinoic acid (W65, H73 and Y387). 
  
 
 
Figure 11-8.  CYP26C1 homology model with at-RA docked in the active site. 
Docking of at-RA in the active site of CYP26C1 suggested that 16-hydroxylation would be the 
preferred site of metabolism by CYP26C1.  In this orientation, at-RA was located approximately 
3.37 Å from the heme iron and within 4 Å of W117, F222, F295, V383 and S384. The Glide 
score for this docking simulation was –9.387. 
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 In order to rationalize the observed metabolic profile of adapalene by CYP26 enzymes, 
the compound was docked into the homology models for all three CYP26 isozymes (Figure 11-
9).  In each case, the adamantyl ring was located in proximity to the heme iron, at a distance of 
approximately 2.864 Å, 2.833 Å and 2.873 Å from the heme of CYP26A1, CYP26B1 and 
CYP26C1, respectively.  Arg90 (CYP26A1), Arg373 (CYP26B1) and Trp65 (CYP26C1) were 
predicted to stabilize this conformation through hydrogen bonding interactions with the 
carboxylate moiety of adapalene.  No orientations supportive of O-demethylation of adapalene 
were observed.  Conversely, when des-adamantyl adapalene was docked in the three 
homology models in an attempt to rationalize the observed switch in metabolic sites, the 
molecule was positioned with the methoxy group oriented towards the heme for all three 
enzymes at an approximate distance of 2.598 Å (CYP26A1), 4.226 Å (CYP26B1) and 2.579 Å 
(CYP26C1).  As with adapalene, Arg90 (CYP26A1) and Arg373 (CYP26B1) were hypothesized 
to stabilize the binding of des-adamantyl adapalene in the respective active sites through 
hydrogen bonding interactions with its carboxylate moiety (Figure 11-9).  In the CYP26C1 
homology model, the carboxylate moiety of des-adamantyl adapalene was located within 3 Å of 
Ser384.   
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Figure 11-9.  CYP26A1, CYP26B1 and CYP26C1 homology models with adapalene and 
des-adamantyl adapalene docked in the active site. 
Docking of adapalene in the active sites of CYP26A1 (A), CYP26B1 (C) and CYP26C1 (E) 
suggested the preferred site of metabolism would be oxidation of the adamantyl moiety with no 
ability for the methoxy group to access the heme iron.  Conversely, docking of des-adamantyl 
adapalene in the active site of CYP26A1 (B), CYP26B1 (D) or CYP26C1 (F) suggested O-
demethylation as the primary route of metabolism. 
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11.3.4. Adapalene Phenotyping.   
Adapalene was a chosen as a representative retinoic acid receptor agonist for further reaction 
phenotyping experiments because of its rates of metabolite formation in all of the recombinant 
CYP26 incubations.  Using a full drug metabolizing enzyme panel, the enzymes responsible for 
the hydroxylation of adapalene were profiled.   The highest rate of adapalene hydroxylation was 
observed with CYP26C1. Additional enzymes which contributed to the formation of the 
hydroxylated metabolite were CYP26B1, CYP3A5, CYP26A1 and CYP2C8 (Figure 11-10).  
Minor contributions were noted for CYP1A2, CYP3A4 and FMO5. 
 
 
Figure 11-10.  Formation of hydroxylated adapalene by recombinant drug metabolizing 
enzymes. 
Reaction phenotyping experiments in recombinant enzymes identified the CYP26 enzymes, as 
well as CYP2C8 and CYP3A5, as major contributors to the hydroxylation of the adamantyl 
moiety of adapalene.   
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11.4. Discussion 
Within the cytochrome P450 family of drug metabolizing enzymes, the CYP26 sub-family 
(CYP26A1, CYP26B1 and CYP261) plays a role in the homeostatic regulation of retinoic acid 
and has been shown to be capable of metabolizing the xenobiotic compound tazarotenic acid 
(Ray et al., 1997; Taimi et al., 2004; Guengerich, 2006; Lutz et al., 2009; Thatcher and 
Isoherranen, 2009; Ross and Zolfaghari, 2011; Foti et al., 2016).  As mentioned previously, 
while both CYP26A1 and CYP26B1 share relatively broad expression patterns (less so for 
CYP26C1), relatively little information exists about the role the enzymes may play in the 
metabolism of xenobiotic compounds (Xi and Yang, 2008; Thatcher and Isoherranen, 2009; 
Thatcher et al., 2010; Topletz et al., 2012; Brown et al., 2014). To that end, the primary focus of 
the work presented in this manuscript was the further characterization of the in vitro metabolic 
capabilities of CYP26A1, CYP26B1 and CYP26C1.   
 While multiple homology models designed to assess the active site characteristics of 
CYP26A1 and CYP26B1 have been reported, much less is known about CYP26C1  (Gomaa et 
al., 2006; Karlsson et al., 2008; Gomaa et al., 2011a; Gomaa et al., 2011b; Saenz-Mendez et 
al., 2012; Foti et al., 2016).  It has been previously determined that while CYP26C1 shares a 
43% and 51% similarity in regard to the amino acid sequences of CYP26A1 and CYP26B1, 
respectively, its enzymatic profile differs somewhat from the other CYP26 isozymes (Taimi et 
al., 2004).  Examination of the CYP26C1 homology model suggested that similar to CYP26A1 
and CYP26B1, ligand interactions within the active site of CYP26C1 are primarily driven by 
lipophilic interactions coupled with amino acid residues capable of hydrogen bonding a 
carboxylate moiety as would be expected for an enzyme whose primary function is the 
metabolism of endogenous retinoids.  The lipophilic triad of one tryptophan residue and two 
phenylalanine residues as key determinants of active site architecture appear to be conserved 
across the three CYP26 isozymes (CYP26A1: Trp112, Phe222, Phe299; CYP26B1 and 
CYP26C1: Trp117, Phe222 and Phe295).  Similar to CYP26A1 (Arg90), a single binding 
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orientation within the active site of CYP26C1 appear to predominate, with the location of the 
carboxylate moiety being determined through interactions with Trp65, His73 and Tyr387 (Figure 
11-7).  Conversely, CYP26B1 appears to be capable of accommodating multiple binding 
orientations through carboxylate interactions with either Trp65 or Arg373 (Figure 9-3) (Foti et al., 
2016).  Interestingly, when at-RA was docked in the active site of CYP26C1, the preferred 
orientation suggested that formation of 16-hydroxy-at-RA would be the predominant metabolite, 
as opposed to what was observed with homology models of CYP26A1 and CYP26B1, where 
the models predicted formation of 4-hydroxy-at-RA to predominate.  Though limited, in vitro data 
suggests that CYP26C1 is capable of catalyzing the metabolism of at-RA at multiple locations 
(Taimi et al., 2004). 
 Initial experiments aimed at determining the ability of the CYP26 enzymes to metabolize 
retinoic acid receptor agonists and antagonists indicated many of the compounds are 
metabolized by the CYP26s, many to an appreciable extent (Table 11-2).  The compound with 
the greatest depletion over 20 minutes differed for each enzyme (CYP26A1, SR11237; 
CYP26B1, tazarotenic acid; CYP26C1, MM11253), suggesting differences in the catalytic 
profiles of each enzyme, and differences in the extent of metabolism between CYP26 and 
CYP2C8 or CYP3A4, two enzymes with overlapping substrate specificities with CYP26, were 
also observed.  A screen for oxidative metabolites of the retinoic acid receptor agonists and 
antagonists identified a number of +16 amu metabolites which, as expected, were located on 
the end of the molecule most distal from the carboxylate moiety.  Earlier in silico efforts also 
suggested the potential for adapalene and other retinoic acid-like compounds to be oxidized at 
multiple sites that were generally distal from the carboxylate moiety (Sloczynska et al., 2015).  
In a number of cases, however, discrepancies were observed when the rates of metabolite 
formation (Figure 11-4) were compared to the rates of compound depletion (Figure 11-3), as in 
the case of SR11373 and CYP26A1, where substrate depletion appears to be rapid but 
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metabolite formation is low compared to the other compounds.  The finding suggests alternative 
routes of metabolism which were not adequately captured by the screen for +16 amu 
metabolites and warrants further investigation.   
 Adapalene was selected for further profiling based on its selectivity for the CYP26 
isoforms over CYP2C8 or CYP3A4 as well as the observed rates of substrate depletion and 
metabolite formation (especially CYP26B1 and CYP26C1) as shown in Figures 11-3 and 11-4.  
The retinoic acid receptor agonist is a structurally-related naphthoic acid analog of retinoic acid 
that is primarily prescribed in the treatment of acne vulgaris (Brogden and Goa, 1997; Waugh et 
al., 2004; Alirezai et al., 2007; Irby et al., 2008).  The introduction of the relatively large 
adamantyl moiety to the molecule presumably serves three purposes, namely mimicking the -
ionone ring of at-RA, limiting its percutaneous flux for toxicological purposes and providing steric 
hindrance around a metabolically favorable O-demethylation site (Pierard et al., 2009).  
Information around the routes of metabolism for adapalene is sparse, perhaps due to its limited 
absorption into circulation following topical administration  
(DIFFERIN_(Adapalene)_Prescribing_Information).  When adapalene was incubated with 
recombinant CYP26A1, CYP26B1 or CYP26C1, a single hydroxylated metabolite was 
observed, with fragmentation patterns from mass spectral analyses suggesting hydroxylation on 
the adamantyl ring (Figure 11-5), with no evidence of adapalene O-demethylation observed.  To 
test the hypothesis that lack of O-demethylation was due to steric hindrance from the adamantyl 
moiety, a des-adamantyl analog of adapalene was incubated in vitro with the three CYP26 
isozymes.  Upon incubation, a single O-demethylated metabolite was observed, with no 
additional metabolites being identified (Figure 11-6).  Indeed, when adapalene was 
computationally docked into the active sites of CYP26A1, CYP26B1 and CYP26C1, a single 
binding orientation was observed, with the adamantyl ring system positioned within 3 Å of the 
heme prosthetic group (Figure 11-9).  In this orientation, the methoxy group was unable to 
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obtain a metabolically favorable position in the active site, supporting the observed in vitro data 
and the role of the adamantyl ring in sterically hindering access of the methoxy hydrogens to the 
heme.  Further, when the des-adamantyl analog was docked, the models predicted the methoxy 
group to be oriented towards the heme iron, suggesting O-demethylation to be the primary site 
of metabolism (Figure 11-9).  The docking orientation of adapalene in the CYP26A1 and 
CYP26B1 models was similar to that previously reported for tazarotenic acid (Foti et al., 2016). 
 Given the observed catalysis of adapalene oxidation by CYP26A1, CYP26B1 and 
CYP26C1, experiments were undertaken to assess the relative contribution of the CYP26 
enzymes versus other P450 isoforms to the overall metabolism of adapalene.  Monitoring for the 
single hydroxylation product observed, CYP26C1, CYP26B1, CYP3A5, CYP2C8 and CYP26A1 
were the major contributors to adapalene hydroxylation in vitro.  Minor contributions were noted 
for CYP1A2, CYP3A4 and FMO5.  The expression of CYP26A1, CYP26B1 and CYP26C1 
mRNA in human skin cells has been reported, and as such, the potential exists for these 
enzymes to play a role in the metabolism of topically administered adapalene (Loudig et al., 
2000; Abu-Abed et al., 2002; Taimi et al., 2004).  However it is important to note that the relative 
protein expression levels of the CYP26 enzymes compared to the other cytochrome P450 
enzymes is not yet understood and as such, additional efforts will be needed to conclusively 
determine the role of the CYP26s in the metabolism of adapalene and other retinoic acid 
receptor agonists and antagonists.   
In conclusion, the results presented in this chapter further support the role of the CYP26 
family of cytochrome P450 family of drug metabolizing enzymes in the metabolism of xenobiotic 
compounds.  To our knowledge, it also describes the first homology model of CYP26C1 based 
on the crystal structure of CYP120.  Comparison of the active site features of the CYP26C1 
homology model to models of CYP26A1 and CYP26B1 suggest similar binding interactions that 
facilitate ligand recognition across the CYP26 isozymes. The data presented herein also 
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suggest that for topically administered compounds such as adapalene, enzymes such as 
CYP26A1, CYP26B1 or CYP26C1 may play a role in their metabolism.  The increased 
understanding gained from characterizing the active sites of all three CYP26 enzymes and 
applying those learnings to identify their contributions to the metabolism of xenobiotics serves to 
significantly increase the awareness of the importance of CYP26A1, CYP26B1 and CYP26C1 in 
the field of drug metabolism.   
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12. Chapter V:  General Conclusions 
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Retinoic acid is a homeostatically-controlled signaling molecule that regulates gene 
expression through interactions with the retinoic acid receptors, resulting in its key role in 
dermatological, immunological and neurological function (Asselineau et al., 1989; Duester, 
2008; Niederreither and Dolle, 2008; Raverdeau et al., 2012; Ransom et al., 2014; Raverdeau 
and Mills, 2014; Cunningham and Duester, 2015).  The initial steps in retinoic acid synthesis 
involve the formation of retinal from retinol (vitamin A), catalyzed by alcohol dehydrogenases 
and short-chain dehydrogenases, and the subsequent conversion of retinal to retinoic acid, 
catalyzed by retinaldehyde dehydrogenases (Roos et al., 1998; Chen et al., 2000b; Zhang et al., 
2000; Marill et al., 2002).  Retinoic acid is oxidatively metabolized to 4-hydroxy-, 16-hydroxy-, 
and 18-hydroxyretinoic acid, with CYP26A1, CYP26B1 and CYP26C1 having been 
characterized as the primary metabolic enzymes involved in the metabolism of at-RA and its 
metabolites with minor contributions from CYP2C8, CYP2C9 and CYP3A (Leo et al., 1989; Ray 
et al., 1997; Sonneveld et al., 1998; Nadin and Murray, 1999; Chen et al., 2000a; Marill et al., 
2000; McSorley and Daly, 2000; Marill et al., 2002; Taimi et al., 2004; Guengerich, 2006; Lee et 
al., 2007; Lutz et al., 2009; Thatcher and Isoherranen, 2009; Thatcher et al., 2010; Helvig et al., 
2011; Ross and Zolfaghari, 2011; Topletz et al., 2012; Nelson et al., 2013a).   
While the understanding around the role of CYP26s in the metabolism of endogenous 
ligands has rapidly increased, knowledge of the role of these enzymes in the metabolism of 
xenobiotic compounds has been lacking.  Combining the fact that CYP26A1 and CYP26B1 are 
expressed in human skin with the topical administration route of current retinoid-based 
interventions, there is clear possibility for the CYP26s to also contribute to the metabolism of 
synthetic retinoids (Heise et al., 2006; Osanai and Lee, 2011; Topletz et al., 2012). Though less 
is known about the expression and functional relevance of CYP26C1, the isoform shares a 43% 
and 51% sequence similarity in regard CYP26A1 and CYP26B1, respectively, and its catalytic 
preferences are thought to differ slightly from CYP26A1 and CYP26B1 (Taimi et al., 2004).  
Adding importance are the current efforts to design retinoids that do not have the 
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pharmacokinetic liabilities of at-RA, namely autoinduction of CYP26A1 and CYP26B1 (Muindi et 
al., 1992; Ray et al., 1997; Sonneveld et al., 1998; Tay et al., 2010).  Further, while various 
efforts are underway to evaluate the inhibition of CYP26 in regard to pharmacological outcomes, 
less attention has been focused on the potential for clinically relevant drug interactions as a 
result of their inhibition.  To that end, efforts to understand and characterize the structural 
aspects of CYP26A1, CYP26B1 and CYP26C1 which define the metabolic and inhibitory 
properties of the enzymes are highly warranted and may lend additional understanding around 
the development of new retinoid-like therapies.   
A homology model approach based on the crystal structure of cyanobacterial CYP120 
(pdb 2VE3) was chosen as the desired method to characterize the active sites and ligand 
binding properties of CYP26A1, CYP26B1 and CYP26C1.  While CYP26A1 and CYP26C1 
sequences were used directly from the currently available sequences (CYP26A1: GenBank ID: 
2688846, UniProtKB O43174; CYP26C1: GenBank ID: 340665, UniProtKB Q6V0L0), previous 
work suggested potential discrepancies between the currently accepted gene sequence for 
CYP26B1 (NCBI Reference Sequence: NP_063938.1; UniProtKB Q9NR63, GenBank ID: 
56603) and that of commercially available clones.  It was determined that the amino acid 
residues at position 64 and 260 of the CYP26B1 protein sequence were an arginine (64) and 
serine (260), rather than a histidine and glycine as previously reported (White et al., 2000).  
From a functional aspect, however, neither residue appears to be directly involved in ligand 
binding.   
A comprehensive analysis of three homology models suggests that all three CYP26 
isoforms have relatively conserved hydrophobic regions within the active site and unique 
domains capable of stabilizing interactions with acidic groups such as the carboxylate moiety of 
at-RA.  Three hydrophobic amino acids including a tryptophan residue and two phenylalanine 
residues appear to combine to delineate the active site boundaries of each enzyme and be 
involved in key hydrophobic bonding interactions: CYP26A1 – Trp112, Phe222, Phe299; 
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CYP26B1 and CYP26C1 – Trp117, Phe222 and Phe295.  Spatially, CYP26A1 (Arg90) and 
CYP26C1 (Trp65, His73 and Tyr387) appear to promote a single binding orientation for 
molecules with a terminal acidic moiety while the active site of CYP26B1 appears to have two 
regions (Trp65/Tyr372 or Arg373) capable of interacting with acidic molecules (Foti et al., 2016).  
Earlier homology models of CYP26A1 or CYP26B1 have proposed Arg64 (Shimshoni et al., 
2012), Arg86 (Gomaa et al., 2006) or Arg90 (Karlsson et al., 2008) for CYP26A1 and Arg95 and 
Ser369 for CYP26B1 (Karlsson et al., 2008; Saenz-Mendez et al., 2012).  The models in this 
thesis, along with the CYP26A1 model in the paper by Shimshoni et al., are the only models 
currently supported by site of metabolism data for at-RA or other retinoids.  Analysis of the 
active site volume of CYP26A1 (918 Å3), CYP26B1 (977 Å3) and CYP26C1 (1090 Å3) identified 
similar binding capabilities for all the CYP26 isoforms and suggest the ability to bind not only 
endogenous retinoic acid but also larger xenobiotics, perhaps similar to what is observed for 
many of the other drug metabolizing cytochrome P450 enzymes.   
While the homology models used in the current work were based on CYP120, previously 
published homology models of CYP26 have also evaluated CYP2C8 as a possible template, as 
it has been shown to be capable of binding retinoic acid and structurally related analogs and is 
currently the only metabolic enzyme which has been successfully crystallized while binding a 
retinoic acid isomer  (Leo et al., 1989; Nadin and Murray, 1999; Yamazaki and Shimada, 1999; 
McSorley and Daly, 2000; Marill et al., 2002; Schoch et al., 2008; Saenz-Mendez et al., 2012).  
Given the functional similarities of CYP26A1, CYP26B1 and CYP2C8, the question of whether 
or not similarities exist among the active site characteristics of the three enzymes must be 
addressed. As inferred, superimposition of the crystal structure of CYP2C8 (pdb 1PQ2) with the 
CYP26 homology models indicated a high degree of similarity and identified amino acid 
residues capable of hydrogen bonding with carboxylic acid moieties in similar regions of their 
respective active sites.  Similar to the CYP26 residues noted above, analysis of the crystal 
structure of CYP2C8 identified a key role for Gly98, Asn99 and Ser100 in orienting the 
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carboxylate of 9-cis-retinoic acid in the active site of CYP2C8 (Schoch et al., 2004; Schoch et 
al., 2008).  The overall similarities provide a strong basis for the pharmacophores of CYP2C8 
and CYP26A1 or CYP26B1 to exhibit significant similarities.   
Though the ability to computationally dock a known enzyme inhibitor into a homology 
model of the enzymes implies that the structural characteristics of the model sufficiently capture 
the key attributes of the actual enzyme, the results give no indication as to whether or not the 
proposed binding orientation of the inhibitor is correct or not.  Conversely, being able to correctly 
predict the orientation of a ligand in the active site of the enzyme that is consistent with known 
sites of metabolism of the ligand suggests the model is also capable of correctly orienting the 
ligand in the active site of the enzyme.  As the reaction mechanism for the metabolism of at-RA 
to 4-hydroxyretinoic acid includes a hydrogen atom abstraction step at a pro-chiral center, the 
resulting orientations of at-RA in the active sites of the CYP26 models presented a key 
opportunity to test the robustness of each model.    Further, previously published reports have 
shown that CYP26A1 stereoselecively catalyzes the formation of 4-(S)-hydroxy-at-RA while 
CYP26B1 is non-stereoselective in the metabolism of at-RA (Shimshoni et al., 2012; Topletz, 
2013).  Suggesting a high degree of structural integrity of the current models, when at-RA was 
computationally docked in the active site of the CYP26A1 model, only the hydrogen atom which 
when abstracted would lead to the formation of 4-(S)-hydroxy-at-RA was oriented towards the 
heme iron, with no resolved poses being able to support formation of 4-(R)-hydroxy-at-RA.  
Alternatively, the CYP26B1 homology model was able to resolve docking orientations which 
would lead to formation of either enantiomer of 4-hydroxy-at-RA, indicating that the key 
structural anomalies between the CYP26A1 and CYP26B1 which result in the stereoselective 
(or lack thereof) formation of 4-hydroxy-at-RA are adequately described by the models.  
Somewhat surprisingly, when at-RA was computationally docked in the CYP26C1 homology 
model, formation of 16-hydroxy-at-RA was suggested to the preferred metabolic transformation, 
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contrary to the results from the CYP26A1 and CYP26B1 homology models.  This is perhaps 
supported by the limited in vitro data suggesting that the CYP26s metabolize at-RA at multiple 
locations (Taimi et al., 2004). 
Though the ligand binding and resulting metabolism of at-RA by the CYP26s has been 
extensively characterized, there have not been any xenobiotic compounds identified as 
substrates for metabolism by the CYP26 family of enzymes.  However, given the reported 
expression of CYP26A1 and CYP26B1 mRNA in human skin combined with the topical route of 
administration used for many retinoids and retinoic acid agonists and antagonists, we 
hypothesized that CYP26 may also play a role in the metabolism of these compounds (Heise et 
al., 2006; Osanai and Lee, 2011; Topletz et al., 2012).  Utilizing in vitro metabolic stability 
assays, a number of retinoids were identified as substrates of CYP26, some to significant 
extents.  Interestingly, the metabolic pattern was both substrate and enzyme dependent.  For 
example, the retinoid with the highest rate of clearance over 20 minutes was different for each 
of the CYP26 isoforms, with SR11237, tazarotenic acid, and MM11253 being metabolized to the 
greatest extent by CYP26A1, CYP26B1 and CYP26C1, respectively.  When quantitatively 
looking at the sites of metabolism of these compounds by CYP26, as expected, all of the 
compounds were oxidatively metabolized on the portion of the retinoid most opposite from the 
carboxylic acid functional group.  This is in agreement with previously published computational 
studies suggesting that compounds such as adapalene generally tend to be oxidized at multiple 
sites by cytochrome P450 enzymes on the portion of the molecule most distal from the 
carboxylic acid (Sloczynska et al., 2015).  Finally, it should be pointed out that metabolite 
formation rates did not always correlate with the rate of substrate depletion, suggesting that 
metabolites other than a simple hydroxylation may be formed by the CYP26 enzymes.   
Based on the in vitro metabolism data, initial efforts focused on tazarotene, an acetylenic 
retinoid pro-drug which is hydrolyzed to tazarotenic acid upon topical administration and which 
is used to treat abnormal keratinocyte proliferation as well as adapalene, a naphthoic acid 
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containing retinoid that is generally used in the treatment of acne vulgaris  (Brogden and Goa, 
1997; Duvic, 1997; Madhu et al., 1997; Tang-Liu et al., 1999; Menter, 2000; Yu et al., 2003; 
Waugh et al., 2004; Attar et al., 2005; Alirezai et al., 2007; Irby et al., 2008; Talpur et al., 2009).  
Docking of tazarotenic acid in the active site of CYP26A1 and CYP26B1 identified a number of 
the same residues involved in orienting the compound in the active site as those important in 
binding retinoic acid.  Residues such as Trp112, Phe222, Phe299, Thr304, Pro369 and Val370 
(CYP26A1) and Trp65, Trp117, Thr121, Phe222, Phe295, Ser369, Val370 and Pro371 
(CYP26B1) appear to be key in both delineating the steric boundaries of the active sites as well 
as in substrate binding (Gomaa et al., 2008; Karlsson et al., 2008; Gomaa et al., 2011a; Gomaa 
et al., 2011b; Saenz-Mendez et al., 2012).  Perhaps more importantly, the ligand binding 
orientations resolved from the computational docking studies were supported by the results 
obtained from in vitro metabolite elucidation efforts which confirmed that tazarotenic acid is 
metabolized by CYP26A1 and CYP26B1 only on the benzothiopyranyl moiety of the molecule.   
 In order to verify the utility of the homology models with a second retinoid-like molecule 
as well as to assess the ability of CYP26 to metabolize compounds with sterically bulky 
functional groups, the metabolism of adapalene by CYP26A1, CYP26B1 and CYP26C1 was 
evaluated.  As previously mentioned, the metabolism of many retinoids (as well as retinoic acid) 
occurs distal to the carboxylate moiety and as such, one can assume that the aim of including a 
sterically-hindering adamantyl group to the molecule was to block metabolic access to a 
energetically favorable O-demethylation pathway as well as to limit systemic exposure of 
adapalene after topical administration (Pierard et al., 2009).  Indeed, in vitro metabolic 
incubations with adapalene and CYP26 identified a single site of oxidation presumed to be on 
the adamantyl ring.  O-demethylation of adapalene was not observed.  The in vitro evidence 
corroborated computational docking results with adapalene which suggested that the adamantyl 
ring would be the primary site of metabolism, with the methoxyl moiety unable to gain a 
metabolically favorable orientation to the heme iron.  When a des-adamantyl version of 
135 
 
adapalene was computationally created and docked in the active site of the CYP26A1, 
CYP26B1 and CYP26C1 homology models, each model predicted the compound to be oriented 
in such a manner that O-demethylation would be the primary route of metabolism.  Indeed, 
when this compound was synthesized and incubated with recombinant CYP26 membrane 
preparations, O-demethylation was the only metabolite observed, with no evidence of any other 
routes of metabolism.  Taken as a whole, the data suggests that each of the CYP26 isoforms 
may be capable of accommodating sterically hindering moieties while metabolically switching to 
more favorable routes of metabolism, a fact which should be considered in the design of new 
retinoid therapeutics aimed at overcoming the pharmacokinetic shortfalls of at-RA.   
To determine the overall contributions of the CYP26s to the metabolism of tazarotenic 
acid and adapalene, reaction phenotyping experiments were undertaken.  Earlier reports have 
suggested that CYP2C8, FMO1 and FMO3 are primarily responsible for the sulfoxidation of 
tazarotenic acid, though these experiments were not carried out at clinically relevant 
concentrations of tazarotenic acid (Attar et al., 2003).  There is no data currently available on 
the enzymes responsible for the metabolism of adapalene.  At clinically relevant concentrations 
(100 nM), CYP26A1 and CYP26B1 were the two drug metabolizing enzymes which resulted in 
the greatest formation of tazarotenic acid sulfoxide and hydroxytazarotenic acid.  Further, 
CYP26B1 and CYP26C1 showed the highest degree of adapalene hydroxylation, with 
CYP26A1 also playing a role.  Additional drug metabolizing enzymes also were involved in the 
metabolism of tazarotenic acid (CYP2C8, CYP2C9, CYP2J2, CYP3A4, CYP3A5, CYP3A7 and 
aldehyde oxidase) and adapalene (CYP3A5, CYP2C8, CYP1A2, CYP3A4 and FMO5), though 
none to the extent of the CYP26s.  As mRNA expression of CYP26A1, CYP26B1 and CYP26C1 
in human skin cells has been previously reported, the possibility exists for CYP26 to play a role 
in the disposition of these compounds after topical administration (Loudig et al., 2000; Abu-Abed 
et al., 2002; Taimi et al., 2004).  One caveat, however, is the lack of protein expression levels 
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for CYP26A1, CYP26B1 or CYP26C1 relative to other drug metabolizing enzymes in the skin, a 
piece of information that is critical to determining the overall contribution of the CYP26s to the 
metabolism of topically administered compounds.  
 After establishing the role of CYP26 in the metabolism of xenobiotic compounds, the 
potential for the enzymes to be involved in clinically-relevant drug interactions was explored.  
Taking advantage of the structural similarities between CYP26A1, CYP26B1 and CYP2C8, a 
set of known CYP2C8 inhibitors was used as the starting point for evaluating CYP26-mediated 
drug interactions.  Using the recently developed tazarotenic acid sulfoxidation assay as a probe 
reaction of CYP26 activity in vitro, the inhibitory potency of known CYP26 and CYP2C8 
inhibitors was measured.  A comparison of IC50 values generated using tazarotenic acid versus 
9-cis-retionic acid as the probe substrate indicated a statistically significant correlation between 
the two assays, though ultimately, the potential for differential inhibition profiles using the two 
assays cannot be ruled out.  Of interest, more potent inhibition values were obtained with 
CYP26A1 when tazarotenic acid was the probe substrate and with CYP26B1 when 9-cis-
retinoic acid was the substrate.  
 CYP2C8 is known to be involved in a number of clinically meaningful drug interactions 
with xenobiotics such as fluvoxamine, rosiglitazone, gemfibrozil, montelukast, rosiglitazone, 
pioglitazone, repaglidide, cerivastatin and loperamide (Backman et al., 2002; Niemi et al., 2003; 
Deng et al., 2005; Jaakkola et al., 2005; Niemi et al., 2006; Tornio et al., 2008; Karonen et al., 
2010; Honkalammi et al., 2011).  Furthermore, a significant amount of effort has gone into the 
characterization of the in vitro inhibition profile of CYP2C8 as well (Walsky et al., 2005; 
VandenBrink et al., 2011).  When a panel of CYP2C8 inhibitors was screened for inhibition of 
CYP26A1 or CYP26B1, a number of potent and selective inhibitors were identified, including 
quercetin, fluconazole, benzbromarone, and zafirlukast for CYP26A1 and repaglinide for 
CYP26B1.  The results suggest promising possibilities in terms of exploiting the active site 
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characteristics of each CYP26 isoform to identify new chemical matter that will result in selective 
chemical inhibition of one of the CYP26 isoforms.  A comparison of the obtained CYP26A1 IC50 
values with previously reported IC50 values for CYP2C8 revealed a statistically significant 
correlation (r2 = 0.849), implying  a potential overlap in the inhibitory pharmacophores of the two 
enzymes.  Similar to what has been previously reported for compounds such as R115866, 
R116010 and ketoconazole, an in depth characterization of the spectral binding properties of 
clotrimazole revealed that the compound inhibits CYP26A1, CYP26B1 and CYP2C8 through 
type II heme-binding interactions (Thatcher et al., 2011).  Computational docking experiments 
supported these findings, with the sp2 nitrogen of clotrimazole’s imidazole ring oriented within 3 
Å of the heme iron in both homology models.   
 In order to translate the in vitro findings to potential in vivo outcomes, the well accepted 
approach of comparing in vitro inhibition potencies (IC50 or Ki) to free inhibitor concentrations in 
vivo ([I]) was utilized.  In general, [I]/Ki values of greater than 1 suggest the likely onset of a 
clinically significant drug interaction while any values between 0.1 and 1 imply that a drug 
interaction is possible (Bjornsson et al., 2003a; Bjornsson et al., 2003b; Kosugi et al., 2012).  
Using this approach, clotrimazole and fluconazole were identified as two potentially clinically 
relevant inhibitors of CYP26.  The observed data suggests that fluconazole may have the 
potential to systemically inhibit CYP26 activity while the topical administration route of 
clotrimazole would most likely limit CYP26 drug interactions to the skin (Sawyer et al., 1975).  
Further, the data would seem to give credence to the role of CYP26 in previously observed drug 
interactions between fluconazole or clotrimazole and at-RA.  For example, in at least one case 
study, co-administration of at-RA and fluconazole resulted in a 4-fold increase in the plasma 
exposure of at-RA, though the overall role of CYP26 in this interaction remains to be determined 
(Schwartz et al., 1995).  In a second example, an increase in at-RA associated side effects were 
observed when at-RA was dosed with fluconazole and abated upon discontinuation of the 
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fluconazole regimen (Vanier et al., 2003).  Pre-clinically, co-dosing of clotrimazole and at-RA to 
retinoic acid resistant cell lines resulted in the onset of cellular differentiation while co-
administration to embryonic carcinoma cells resulted in the overall inhibition of at-RA 
metabolism (Williams and Napoli, 1987; Kizaki et al., 1996; Tiboni et al., 2009).  As with the 
clinical data, the contributions of CYP26 to these drug interactions are worthy of additional 
consideration.  Taken as a whole, the observed inhibition profiles of CYP26 in vivo suggest that 
the potential for meaningful CYP26-mediated drug interactions to occur in humans is a distinct 
possibility.   
 In conclusion, the research presented in this thesis details the first homology models of 
CYP26A1, CYP26B1 and CYP26C1 that are supported by metabolism data both from at-RA as 
well as xenobiotic substrates.  In the process, the first known xenobiotic substrate of CYP26A1 
and CYP26B1, tazarotenic acid, was identified.  Subsequently, the catalytic pharmacophore of 
CYP26 was expanded to include other retinoids and retinoic acid receptor agonists and 
antagonists such as adapalene.  In addition to the contributions of the enzymes to xenobiotic 
metabolism, their role in drug interactions was investigated with significant similarities to the 
inhibition profile of CYP2C8 being identified.  Combined with the homology models, the data 
was used in an iterative fashion to compare the structural similarities and differences among the 
three CYP26 isoforms that lead to their catalytic and inhibitory properties and suggested the 
ability of the enzymes to bind larger, drug-like molecules in addition to their known 
pharmacophores.  In its entirety, the data serves to increase the understanding of CYP26 ligand 
binding properties, information that should serve to further the pursuit of CYP26 as a drug target 
and expand the field of knowledge around its contributions to xenobiotic drug metabolism and 
drug interactions. 
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